

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

VOL. 19, NO. 1 FEB. 1992

Message from the Editor xvii
 List of Ad Hoc Reviewers xviii

SPECIAL FEATURE

1991 Richardson Lecture — Diabetic Neuropathy: Models, Mechanisms and Mayhem
P.K. Thomas 1

ORIGINAL ARTICLES

The Organization of Stepping in Patients with Parkinson's Disease: Bradykinesia or Discoordination?
Anne Beuter, Lise Carrière, Bradford McFadyen and Serge Gauthier ... 8

Proteolytic Activity During the Growth of C6 Astrocytoma in the Murine Spheroid Implantation Model
Indrasen S. Vaithilingam, Warren McDonald, Eric C. Stroude, Robert A. Cook and Rolando F. Del Maestro 17

Crown of Microfilaments in the Extending Cytoplasmic Processes of Medulloblastoma Glial Progenitors
Bernard L. Maria, Robert Cumming and Loretta Sukhu 23

A Comparison of CT Contrast Enhancement and BUDR Labeling Indices in Moderately
 and Highly Anaplastic Astrocytomas of the Cerebral Hemispheres
Michael W. McDermott, Hendrikus G.J. Krouwer, Akio Asai, Satoyuki Ito, Takao Hoshino and Michael D. Prados 34

Arteriovenous Malformations of the Brain in Children: A Forty Year Experience
Douglas Kondziolka, Robin P. Humphreys, Harold J. Hoffman, E. Bruce Hendrick and James M. Drake..... 40

Is Cerebral Arteritis the Cause of the Landau-Kleffner Syndrome? Four Cases in Childhood with Angiographic Study
Ignacio Pascual-Castroviejo, V. López Martín, A. Martínez Bermejo and A. Pérez Higuera 46

Lesions of the Tunica Media in Traumatic Rupture of Vertebral Arteries: Histologic and Biochemical Studies
M.S. Pollanen, J.H.N. Deck, L. Boutilier and G. Davidson 53

Concerning the Mechanism of Recovery in Stroke Hemiplegia
C. Miller-Fisher 57

A Comparison of Methods to Assess the Excitability of Lower Motoneurons
Ivan G. Milanov 64

Nociceptive Threshold and Physical Activity
Régis Guieu, Olivier Blin, Jean Pouget and Georges Serratrice 69

Prevalence of Multiple Sclerosis in Barrhead County, Alberta, Canada
Sharon Warren and K.G. Warren 72

Neurodevelopmental Criteria in the Classification of Congenital Motor Nystagmus
J.E. Jan, J.D.A. Carruthers and G. Tillson 76

Beta-Adrenoceptor Modulation in a Case of Pure Autonomic Failure
Sergio Perna, Rocco Leone, Maria Jussie Farace, Vincenzo Brescia-Morra, Giuseppe Campanella and Gregorio Brevetti 80

Syringomyelia as a Complication of Tuberculous Meningitis
Michael G. Fehlings and Mark Bernstein 84

Myasthenia Gravis in a Child with Sequelae of Opsoclonus-Myoclonus Syndrome
Angus A. Wilfong and Fabio Fernandez 88

ABSTRACTS
 Canadian Association of Neuropathologists – Abstracts of the 30th Annual Meeting 90

BOOK REVIEWS 99

NOTES AND ANNOUNCEMENTS xviii

CALENDAR OF EVENTS xviii

INSTRUCTIONS TO AUTHORS xx-xxi

ADVERTISERS INDEX xxviii

VOL. 19, NO. 1 (Supplement) FEB. 1992

Acknowledgement iv
 Introduction v

Frequency and Cause of Parkinson's Disease
A.H. Rajput 103

A Rationale for Dopamine Agonists as Primary Therapy for Parkinson's Disease
C.W. Olanow 108

Prevention and Management of Late Stage Complications in Parkinson's Disease
A. Jon Stoessl..... 113

Amyotrophic Lateral Sclerosis, Parkinson's Disease and Alzheimer's Disease: Phylogenetic Disorders of the Human Neocortex Sharing Many Characteristics
Andrew Eisen and Donald Calne 117

Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson's Disease

William G. Tatton, Carol E. Greenwood, Nadine A. Seniuk and Paul T. Salo 124

Levodopa-Induced Dyskinesia: Facts and Fancy. What does the MPTP Monkey Model Tell Us?
Paul J. Bédard, Baltazar Gomez Mancilla, Pierre Blanchette, Céline Gagnon and Thérèse Di Paolo 134

Positron Emission Tomography in Parkinson's Disease
Barry J. Snow 138

Deprenyl in Parkinson's Disease: Mechanisms, Neuroprotective Effect, Indications and Adverse Effects
Paul Vezina, Erich Mohr and David Grimes 142

Synergistic Interactions of D1- and D2-Selective Dopamine Agonists in Animal Models for Parkinson's Disease: Sites of Action and Implications for the Pathogenesis of Dyskinesias
H.A. Robertson 147

Sustained Release Antiparkinson Agents: Controlled Release Levodopa
Serge Gauthier and Donna Amyot 153

The Place of the Dopaminergic Agonists in the Treatment of Parkinson's Disease: the View from the Trenches
David B. King 156

Future Treatment of Parkinson's Disease
Joseph King Ching Tsui 160

VOL. 19, NO. 2 MAY 1992

ARTICLES

Neuropsychological and Glucose Metabolic Profiles in Asymmetric Parkinson's Disease
Erich Mohr, Ulrike M. Mann, Robert S. Miletich, Margaret Sampson, Terry E. Goldberg, J. David Grimes, and Thomas N. Chase 163

Life-style and Dietary Factors Early and Late in Parkinson's Disease
P. Vieregge, C.v. Maravic and H.-J. Friedrich 170

Forearm P-31 Nuclear Magnetic Resonance Spectroscopy Studies in Oculopharyngeal Muscular Dystrophy
Douglas W. Zochodne, Wilma J. Koopman, Norbert J. Witt, Terry Thompson, Alberta A. Driedger, Dennis Gravelle and Charles F. Bolton 174

Diagnosis and Management of Spinal Epidural Abscess
Gary J. Redekop and Rolando F. Del Maestro 180

Intrathecal Baclofen for Intractable Spinal Spasticity – a Double-blind Cross-over Comparison with Placebo in 6 Patients
H. Hugenholtz, R.F. Nelson, E. Dehoux, R. Bickerton 188

Fracture of Temporal Bone with Exsanguination: Pathology and Mechanism
M.S. Pollanen, J.H.N. Deck, B. Blenkinsop and E.M. Farkas 196

The Anticonvulsant Effects of Vitamin E: A Further Evaluation
Sheldon L. Levy, W.M. Burnham, A. Bishai and Paul A. Hwang 201

The Pharmacology of Chewable Versus Regular Carbamazepine in Chronically Treated Children with Epilepsy
Peter Camfield, Paul Hwang, Carol Camfield, Albert Fraser, Steven Soldin, AK Al-Quadah 204

The Insular Cortex and the Pathophysiology of Stroke-Induced Cardiac Changes – Review Article
Stephen Oppenheimer 208

Photon Radiosurgery: A Clinical Review
Michael R. McKenzie, Luis Souhami, Ervin B. Podgorsak, André Olivier, Jean-Louis Caron and Jean-Guy Villemure 212

Cerebral Aneurysms and Polycystic Kidney Disease: A Critical Review
Andres M. Lozano and Richard Leblanc 222

Clinically Non-Functioning Human Pituitary Adenomas – Review Article
Sylvia L. Asa and Kalman Kovacs 228

Tegmental Pontine Hemorrhages: Clinical Features and Prognostic Factors
Marcelo Lancman, Jorge Norscini, Hripsime Mesropian, Carlos Bardeci, Toselli Bauso and Reubens Granillo 236

Chronic Lymphocytic Leukemia Presenting as a Pituitary Mass Lesion
Jonathon S. Fain, Faramarz Naeim, Donald P. Becker, Andre Van Herle, Fisca Yan-Go, Leonard Petrus and Harry V. Vinters ... 239

Neuroblastoma and Fetal Exposure to Phenytoin in a Child Without Dysmorphic Features
S. Al-Shammri, A. Guberman and E. Hsu 243

XXVIIIth CANADIAN CONGRESS OF NEUROLOGICAL SCIENCES
 Program and Abstracts. 246

CORRESPONDENCE 309

BOOKS RECEIVED 310

BOOK REVIEWS 311

NOTES AND ANNOUNCEMENTS 314

CALENDAR OF EVENTS 315

INSTRUCTIONS TO AUTHORS xxiv

ADVERTISERS INDEX xxxii

VOL. 19, NO. 3 AUG. 1992

ARTICLES

Magnetic Resonance Imaging and ³¹ P Magnetic Resonance Spectroscopy Study of the Effect of Temperature on Ischemic Brain Injury <i>Garnette R. Sutherland, Howard Lesiuk, Paul Hazendonk, James Peeling, Richard Buist, Piotr Kozlowski, Andrzej Jazinski and John K. Saunders</i>	317
Malondialdehyde, Glutathione Peroxidase, and Superoxide Dismutase in Cerebrospinal Fluid During Cerebral Vasospasm in Monkeys <i>R. Loch Macdonald, Bryce K.A. Weir, Tim D. Runzer and Michael G.A. Grace</i>	326
A Canadian Population Survey on the Clinical, Epidemiologic and Societal Impact of Migraine and Tension-Type Headache <i>William Pryse-Phillips, Helen Findlay, Peter Tugwell, John Edmeads, T.J. Murray and R.F. Nelson</i>	333
Comparison of the Efficacy and Safety of Flunarizine to Propranolol in the Prophylaxis of Migraine <i>M.J. Gawel, J. Kreeft, R.F. Nelson, D. Simard and W.S. Arnott</i>	340
The Distinctive Clinical Features of Paraneoplastic Sensory Neuronopathy <i>Colin H. Chalk, Anthony J. Windebank, David W. Kimmel and Philip G. McManis</i>	346
Ventricular Size, Cognitive Function and Depression in Patients with Multiple Sclerosis <i>Campbell M. Clark, Gerald James, David Li, Joel Oger, Donald Paty and Harry Klonoff</i>	352
Amyotrophic Lateral Sclerosis: Interleukin-6 Levels in Cerebrospinal Fluid <i>Charles Krieger, Thomas L. Perry and Hermann J. Ziltener</i>	357
Treatment of Acquired Autoimmune Myasthenia Gravis: a Topic Review <i>Pradeep Verma and Joël Oger</i>	360
MRI Diagnosis of Brainstem Cavernous Angiomas Presenting as Tumours <i>Mark C. Preul, Jean-Guy Villemure, Richard Leblanc and Raquel del Carpio-O'Donovan</i>	376
Stiff-Person Syndrome <i>Mandar S. Jog, Colin D. Lambert and Anthony E. Lang</i>	383
Spontaneous Disappearance of an Intracranial Aneurysm After Subarachnoid Hemorrhage <i>Mark G. Hamilton and Oliver N.R. Dold</i>	389
Intraventricular Central Neurocytoma <i>M. Giroux, J.P. Farmer, K.M. Meagher-Villemure, A.M. O'Gorman and J.L. Montes</i>	392
John G. Humphrey – A Remembrance (1928-1991) <i>John Wherrett</i>	397
Neurocritical Care – Highlights from Two Austrian Meetings, December 1991 <i>G.B. Young and C.F. Bolton</i>	398
ABSTRACTS Abstracts of the 31st Annual Meeting of the Canadian Association of Neuropathologists	402
BOOKS RECEIVED	412
BOOK REVIEWS	413
NOTES AND ANNOUNCEMENTS	415
CALENDAR OF EVENTS	416
SPECIAL AWARDS	417
INSTRUCTIONS TO AUTHORS	vi
ADVERTISERS INDEX	xxvi

VOL. 19, NO. 4 NOV. 1992

ARTICLES

Mechanisms of Cerebral Vasospasm Following Subarachnoid Hemorrhage in Monkeys <i>R.L. Macdonald, B.K.A. Weir, M.G.A. Grace, M.H. Chen, T.P. Martin and J.D. Young</i>	419
During Repetitive Forebrain Ischemia, Post-ischemic Hypothermia Protects Neurons from Damage <i>Ashfaq Shuaib, Sadiq Ijaz, Jay Kalra and William Code</i>	428
The Influence of Indomethacin and Guanethidine on Experimental Streptozotocin Diabetic Neuropathy <i>Douglas W. Zochodne and Lam T. Ho</i>	433
Neuropathology of the Acquired Immune Deficiency Syndrome (AIDS): Report of 39 Autopsies from Vancouver, British Columbia <i>Marcia E. Cornford, Janet K. Holden, Michael C. Boyd, Kenneth Berry and Harry V. Vinters</i>	442
Neurological Findings in HIV-Infected Children: A Review of 49 Cases <i>S. Roy, G. Geoffroy, N. Lapointe and J. Michaud</i>	453
Absence of HTLV-I and HTLV-II Proviral Genome in the Brains of Patients with Multiple Sclerosis and Amyotrophic Lateral Sclerosis <i>G.A. Dekaban, A.J. Hudson and G.P.A. Rice</i>	458
Excitatory Amino Acid Receptor Antagonist in Murine Motoneuron Disease (The Wobbler Mouse) <i>Charles Krieger, Thomas L. Perry, Shirley Hansen, Hiroshi Mitsumoto and Tage Honoré</i>	462
The Increased Susceptibility of Women to Multiple Sclerosis <i>P. Duquette, J. Pleines, M. Girard, L. Charest, M. Senecal-Quevillon and C. Masse</i>	466
The Neurology of Cobalamin — Review Article <i>Michael I. Shevell and David S. Rosenblatt</i>	472
Suppression of Spreading Depression of Leão in Neocortex by an N-Methyl-D-Aspartate Receptor Antagonist <i>Richard S. McLachlan</i>	487
Gliomas in Families <i>Y. Ikizler, D.J. van Meyel, D.A. Ramsay, G.L. Abdallah, R.M. Allaster, D.R. Macdonald, W.K. Cavenee and J.G. Cairncross</i>	492
Malignant Astrocytoma of the Optic Nerve in a Child <i>Janice R. Safneck, Lee B. Napier and William C. Halliday</i>	498
Symptomatic Dystonia: Clinical Profile of 46 Brazilian Patients <i>Henrique B. Ferraz and Luis Augusto F. Andrade</i>	504
The Role of Magnetic Resonance Imaging in Acute Transverse Myelitis <i>Sara G. Austin, Chi-Shing Zee and Cheryl Waters</i>	508
Henry Dunn: An Appreciation <i>John U. Crichton</i>	512
Symposium to Honour Henry Dunn <i>John Tibbles</i>	512
CORRESPONDENCE	514
BOOKS RECEIVED	516
BOOK REVIEWS	516
NOTES AND ANNOUNCEMENTS	519
Consensus Statement on Physician Training for the Treatment of Dystonia with Botulinum Toxin	522
XXVIIIth CANADIAN CONGRESS OF NEUROLOGICAL SCIENCES Call for Abstracts	523
CALENDAR OF EVENTS	524
INDEX TO VOLUME 19	525
INSTRUCTIONS TO AUTHORS	vi
ADVERTISERS INDEX	xxiv

Ticlid[®]

TICLID (ticlopidine hydrochloride) 250 mg Tablets

THERAPEUTIC CLASSIFICATION Inhibitor of Platelet Function

ACTION Ticlid (ticlopidine hydrochloride) is an inhibitor of platelet aggregation. It causes a time and dose-dependent inhibition of platelet aggregation and release of platelet factors, as well as a prolongation of bleeding time. The drug has no significant *in-vitro* activity. The exact mechanism of action is not fully characterized, but does not involve inhibition of the prostacyclin/thromboxane pathways or platelet cAMP.

Ticlid interferes with platelet membrane function by inhibiting ADP-induced platelet-fibrinogen binding and subsequent platelet-platelet interactions. The effect of Ticlid on platelet function is irreversible. Template bleeding time is usually prolonged by two to five-fold of baseline values with the therapeutic dose of Ticlid.

Upon discontinuation of Ticlid dosing, bleeding time and other platelet function tests return to normal within one week in the majority of patients.

The correlation between ticlopidine hydrochloride plasma levels and activity is still under investigation. Much of the following data was obtained from older patients corresponding to the age of patients participating in clinical trials (mean age: 63 years).

After oral administration of the therapeutic dose of Ticlid, rapid absorption occurs, with peak plasma levels occurring at approximately 2 hours after dosing. Absorption is at least 80% complete. Administration of Ticlid after meals results in an increased (20%) level of ticlopidine hydrochloride in plasma.

Steady state plasma levels of ticlopidine hydrochloride in plasma are obtained after approximately 14 days of dosing at 250 mg BID. The terminal elimination half-life is 4-5 days. However, inhibition of platelet aggregation is not correlated with plasma drug levels.

Ticlopidine hydrochloride binds reversibly (98%) to plasma proteins, mainly to serum albumin and lipoproteins in a non-saturable manner.

Ticlopidine hydrochloride is metabolized extensively by the liver; no intact ticlopidine hydrochloride is detected in the urine. Unmetabolized ticlopidine hydrochloride is a minor component in plasma after a single dose, but at steady state, ticlopidine hydrochloride is the major component.

Impaired hepatic function resulted in higher than normal plasma levels of unchanged ticlopidine hydrochloride after single doses or after multiple doses.

Inhibition of platelet aggregation is detected within 2 days of administration with 250 mg BID. Maximum platelet aggregation inhibition is achieved 8 to 11 days following dosing with 250 mg BID.

INDICATIONS AND CLINICAL USE Ticlid (ticlopidine hydrochloride) tablets are indicated for reduction of the risk of first or recurrent stroke for patients who have experienced at least one of the following events: Complete Thromboembolic Stroke, Minor Stroke, Reversible Ischemic Neurological Deficit (RIND), or Transient Ischemic Attack (TIA) including Transient Monocular Blindness (TMB).

CONTRAINDICATIONS Ticlid (ticlopidine hydrochloride) is contraindicated in the following conditions: 1. Known hypersensitivity to drug or its excipients. 2. Presence of haematopoietic disorders (such as neutropenia and/or thrombocytopenia). 3. Presence of haemostatic disorder. 4. Conditions associated with active bleeding, such as bleeding peptic ulcer or intracranial bleeding. 5. Severe liver dysfunction.

WARNINGS The following warnings were developed from clinical trial experience with over 2000 patients with cerebrovascular disease who were treated with ticlopidine for as long as 5.8 years.

Neutropenia and Thrombocytopenia: About 2.4% of ticlopidine-treated patients in clinical trials developed neutropenia (defined as an absolute neutrophil count (ANC) below 1.2×10^9 cells/L). The incidence of severe neutropenia (ANC < 0.45×10^9 cells/L) was 0.8%. Severe neutropenia occurs during the first 3-12 weeks of therapy, and may develop quickly over a few days. The bone marrow shows a reduction in myeloid precursors. The condition is reversible, and recovery usually occurs within 1-3 weeks after discontinuation of the drug.

In clinical trials, thrombocytopenia (defined as a platelet count of < 0.8×10^{11} cells/L) has been observed in 0.4% of ticlopidine patients. The incidence of thrombocytopenia in patients on ASA or placebo was 0.3% or 0.4% respectively. The thrombocytopenia may occur as an isolated finding or in combination with neutropenia. Thrombocytopenia occurs during the first 3-12 weeks of therapy, and recovery usually occurs after drug discontinuation.

All patients should have a white blood cell count with a differential count and platelet count performed every 2 weeks during the first 3 months of therapy. The incidence of neutropenia or thrombocytopenia after three months of therapy is not appreciably higher than the background levels observed in control groups, and continued periodic monitoring is not warranted. However, for the duration of ticlopidine therapy, any signs or symptoms suggestive of neutropenia or thrombocytopenia should be promptly investigated with complete blood counts and platelet counts.

Hemorrhagic Complications: Prolongation of bleeding time occurs in subjects treated with Ticlid. Purpura and a few cases of more serious hemorrhagic events such as hematemesis, melena, hemorthorax and intracranial bleeding have been reported. Patients must be instructed to watch for signs of bleeding disorders and to report any abnormality to their physician immediately. Ticlid therapy has to be stopped by the patient if a physician is not immediately available for consultation.

Anticoagulant Drugs: Should be avoided as tolerance and safety of simultaneous administration with Ticlid has not been established.

Hepatic Abnormalities: Most patients receiving ticlopidine hydrochloride showed some increase of their alkaline phosphatase values above their baseline and in one-third the increase exceeded the upper reference range. In 6% the value was greater than twice the upper reference range. These increases in alkaline phosphatase were nonprogressive and asymptomatic. In clinical trials, two cases (0.1%) of cholestatic jaundice accompanied by elevated transaminases alkaline phosphatase, and bilirubin levels above $43 \mu\text{mol/L}$ have been observed. Both patients recovered promptly upon drug discontinuation.

Pregnancy: The safety of Ticlid in pregnancy has not been established. It should not be used in pregnant patients.

Pediatric Use: Safety in children has not been studied. Do not use in pediatric patients.

PRECAUTIONS

Clinical Monitoring: All patients have to be carefully monitored for clinical signs and symptoms of adverse drug reactions (see ADVERSE REACTIONS). The signs and symptoms possibly related to neutropenia (fever, chills, sore throat, ulcerations in oral cavity), thrombocytopenia and abnormal hemostasis (prolonged or unusual bleeding, bruising, purpura, dark stool), jaundice (including dark urine, light coloured stool) and allergic reactions should be explained to the patients who should be advised to stop medication and consult their physician immediately if any of these occur.

Laboratory Monitoring: All patients should have a WBC count with differential and platelet count performed every 2 weeks during the first 3 months of therapy. Thereafter, the WBC counts need only be repeated for symptoms or signs suggestive of neutropenia. Liver function tests should be conducted during therapy with Ticlid (ticlopidine hydrochloride) in response to signs and symptoms suggestive of hepatic dysfunction.

Elective Surgery: Ticlid should be discontinued 10 to 14 days prior to elective surgery or dental extraction and bleeding time and thrombocyte count performed before the procedure if clinically indicated.

Emergency Surgery: Prolonged bleeding during surgery may be a problem in ticlopidine-treated patients. Transfusions of fresh platelets would be expected to improve haemostasis in such patients, but there are no data from clinical trials to confirm this expectation. There are data from clinical pharmacology trials that indicate treatment with glucocorticosteroids can normalize bleeding time in ticlopidine treated subjects, but there is no experience with ticlopidine-treated surgical patients to show that such treatment improves haemostasis.

Selection of Patients: Ticlid should be used only for the established indications (see INDICATIONS) and should not be given to patients with haematopoietic disorders, haemostatic disorders, patients suffering from conditions associated with active bleeding (see CONTRAINDICATIONS) and patients anticipating elective surgery. In clinical trials elderly patients tolerated the drug well, but safety in children and pregnant women has not been established.

Specific Precautions: Liver: Ticlid is contraindicated in patients with severe liver dysfunction or cholestatic jaundice. Mild increase of Alkaline Phosphatase may be seen for the duration of the treatment and is inconsequential in the majority of patients (see WARNINGS and CONTRAINDICATIONS).

Kidneys: Ticlid has been well tolerated in patients with moderately decreased renal function. In severe renal disease, caution and close monitoring are recommended.

Gastrointestinal System: Conditions associated with active bleeding, such as bleeding ulcers, constitute contraindication for Ticlid. Clinical judgement and monitoring of stool for occult blood are required for patients

with a history of ulcerative lesions. Trauma: Ticlid should be discontinued temporarily until the danger of abnormal bleeding is eliminated. A single fatal case of intracranial bleeding following head trauma has been reported. The extent to which Ticlid may have contributed to the severity of the bleeding is unknown.

Drug Interactions: The following table outlines the agents which have been concomitantly administered with ticlopidine hydrochloride and the observed interaction if any:

AGENTS	OBSERVED INTERACTION
Acetylsalicylic acid (ASA)	Potential of ASA's effect on collagen-induced platelet aggregation (see WARNINGS).
Antipyrine and products metabolized by hepatic microsomal enzymes	30% increase in t _{1/2} of antipyrine.
Theophylline	Dose of products metabolized by hepatic microsomal enzymes to be adjusted when starting or stopping concomitant therapy with ticlopidine hydrochloride.
Digoxin	t _{1/2} of theophylline increased from 8.6 to 12.2 hr along with a comparable reduction in its total plasma clearance.
Cimetidine	Approximately 15% reduction in digoxin plasma levels, (little or no change in digoxin's efficacy expected).
Antacids	Chronic administration of cimetidine induced a 50% reduction in clearance of a single dose of ticlopidine hydrochloride.
Phenobarbital	20% decrease in ticlopidine plasma level when administered after antacids.

Other Concomitant Therapy: Although specific interaction studies were not performed, in clinical studies, TICLID was used concomitantly with beta blockers, calcium channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (however see WARNINGS) without evidence of clinically significant adverse interactions.

ADVERSE REACTIONS Most adverse effects are mild, transient and occur early in the course of treatment. In controlled clinical trials of 1 to 5 years duration, discontinuation of Ticlid (ticlopidine hydrochloride) due to one or more adverse effects was required in 20.9% of patients. In these same trials, ASA and placebo led to discontinuation in 14.5% and 6.7% of patients respectively. The incidence rates of adverse reactions listed in the following table were derived from multicenter, controlled clinical trials comparing ticlopidine HCl, placebo, and ASA over study periods of up to 5 years. The rates are based on adverse reactions considered probably drug-related by the investigator. Adverse experiences occurring in greater than one percent of patients treated with Ticlid in controlled clinical trials are shown in the Table below.

PERCENT OF PATIENTS IN CONTROLLED STUDIES

	Ticlid (n=2048) Incidence	ASA (n=1527) Incidence	Placebo (n=536) Incidence		Ticlid (n=2048) Incidence	ASA (n=1527) Incidence	Placebo (n=536) Incidence
Event							
Diarrhea	12.5(6.3)*	5.2(1.8)	4.5(1.7)	Nausea	7.0(2.6)	6.2(1.9)	1.7(0.9)
Dyspepsia	7.0(1.1)	9.0(2.0)	0.9(0.2)	Rash	5.1(3.4)	1.5(0.8)	0.6(0.9)
GI Pain	3.7(1.9)	5.6(2.7)	1.3(0.4)	Neutropenia	2.4(1.3)	0.8(0.1)	1.4(0.4)
Purpura	2.2(0.2)	1.6(0.1)	0.0(0.0)	Vomiting	1.9(1.4)	1.4(0.9)	0.9(0.4)
Flatulence	1.5(0.1)	1.4(0.3)	0.0(0.0)	Pruritus	1.3(0.8)	0.3(0.1)	0.0(0.0)
Dizziness	1.1(0.4)	0.5(0.4)	0.0(0.0)	Anorexia	1.0(0.4)	0.5(0.4)	0.0(0.0)

* Percent of patients (in parentheses) discontinuing clinical trials due to event

The incidence of thrombocytopenia in these controlled studies was 0.4% in the Ticlid and placebo groups of patients and 0.3% in the ASA patient population.

The following rare events have been reported and their relationship to Ticlid is uncertain.

Pancytopenia, hemolytic anemia with reticulocytosis, thrombocytopenic thrombotic purpura, jaundice, allergic pneumonitis, systemic lupus (positive ANA), peripheral neuropathy, vasculitis, serum sickness, arthropathy, hepatitis, nephrotic syndrome, myositis, and hyponatremia.

Gastrointestinal: Ticlid therapy has been associated with a variety of gastrointestinal complaints including diarrhea and nausea. The majority of cases are mild and transient in nature and occur within 3 months of initiation of therapy. Typically, events are resolved within 1-2 weeks without discontinuation of therapy. If the effect is severe or persistent, therapy should be discontinued.

Hemorrhagic: Ticlid has been associated with a number of bleeding complications such as ecchymosis, epistaxis, hematuria, conjunctival hemorrhage, gastrointestinal bleeding, and postoperative bleeding. Intracerebral bleeding was rare in clinical trials with Ticlid, and was no more than that seen with comparator agents (ASA, placebo).

Rash: Ticlopidine hydrochloride has been associated with a maculopapular or urticarial rash (often with pruritus). Rash usually occurs within 3 months of initiation of therapy, with a mean time to onset of 11 days. If drug is discontinued, recovery should occur within several days. Many rashes do not recur on drug challenge. There have been rare reports of more severe rashes.

Altered Laboratory Findings: Hematological: Neutropenia and rarely thrombocytopenia have been associated with Ticlid administration (see WARNINGS).

Liver: Ticlid therapy has been associated with elevations of alkaline phosphatase (See WARNINGS). Maximal changes occur within 1-4 months of therapy initiation. No further progressive increases are seen with continuous therapy. Occasionally patients developed deviations in bilirubin and SGOT.

Cholesterol: Chronic Ticlid therapy has been associated with increased serum cholesterol and triglycerides. Serum levels of HDL-C, LDL-C, VLDL-C, and triglycerides are increased 8-10% after 1-4 months of therapy. No further progressive elevations are seen with continuous therapy. The ratios of the lipoprotein subfractions are unchanged. The effect is not correlated with age, sex, alcohol use, or diabetes.

SYMPTOMS AND TREATMENT OF OVERDOSAGE One case of deliberate overdosage with Ticlid (ticlopidine hydrochloride) has been reported in a foreign postmarketing surveillance program. A 38 year old male took a single 6000 mg dose of Ticlid (equivalent to 24 standard 250 mg tablets). The only abnormalities reported were increased bleeding time and increased SGPT. No special therapy was instituted and the patient recovered without sequelae. Based on animal studies, overdosage may result in severe gastrointestinal intolerance.

In the case of excessive bleeding after injury or surgery, standard supportive measures should be carried out if indicated, including gastric lavage, platelet transfusion and use of corticosteroids.

DOSE AND ADMINISTRATION The recommended dose of Ticlid (ticlopidine hydrochloride) is 250 mg twice daily with food. Ticlid should be taken with meals to minimize gastrointestinal intolerance.

PHARMACEUTICAL INFORMATION

(i) Drug Substance

Description: Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble in water and self buffers to a pH of 3.6. It also dissolves freely in methanol, is sparingly soluble in buffer solutions above pH 6.0, methylene chloride and ethanol, and is slightly soluble in acetone.

(ii) Composition: Ticlopidine hydrochloride tablets are provided, as white film coated tablets containing ticlopidine hydrochloride, citric acid, povidone, microcrystalline cellulose, corn starch, stearic acid powder, magnesium stearate and water. The coating suspension consists of hydroxypropyl methylcellulose, titanium dioxide and polyethylene glycol. The ink for printing contains D&C yellow #10 aluminum lake and FD&C blue #1 aluminum lake.

(iii) Stability and Storage Recommendations: Store at room temperature. Ticlid tablets should be dispensed in light resistant containers. Blister packs should not be exposed to light.

AVAILABILITY Ticlid 250 mg tablets are oval white film coated tablets printed using green ink with Ticlid above half an arrow on one side, "250" above half an arrow on the other side. The tablets are available in 2-week Patient Starter Packs of 28 tablets (2 blisters of 14 tablets). They are also available in boxes of 56 (4 x 14) tablets and 168 (12 x 14) tablets.

For the first 3 months of therapy, only request or dispense the 14 days supply of tablets (see PRECAUTIONS).

Product Monograph available to Health Professionals on request.

REFERENCES 1. Adapted from Feinberg W. Antithrombotic therapy in stroke and transient ischemic attacks. *American Family Physician* 1989;40(Suppl):S35-95. 2. Hass WK et al. Ticlopidine Aspirin Stroke Study (TASS). A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. *N Engl J Med* 1989;321:501-7. 3. Gent M et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. *The Lancet* 1989 Jun;1:215-20. 4. Ticlopidine Aspirin Stroke Study (TASS). Data on file, Syntex Inc., Vol.52, Oct 1989. 5. Compendium of Pharmaceuticals and Specialties, 1992. 6. Ticlid product monograph.



Prescribing Information

ACTION AND CLINICAL PHARMACOLOGY

SIBELIUM® (flunarizine hydrochloride) prevents the deleterious effects of cellular calcium overload by reducing excessive transmembrane fluxes of calcium. Flunarizine does not interfere with normal cellular calcium homeostasis. Flunarizine also has antihistaminic properties.

The effects of flunarizine in the prophylaxis of migraine are most pronounced with regards to the reduction of the frequency of attacks. The severity of migraine attacks improves to a lesser extent, while little or no effect is seen on the duration of migraine episodes.

The pharmacokinetic parameters of orally administered flunarizine are summarized in Table 1.

Flunarizine is well absorbed; peak plasma levels are attained 2 to 4 hours after oral administration in healthy volunteers. Plasma concentrations increase gradually during chronic administration of 10 mg daily, reaching a steady state level after 5 to 6 weeks of drug administration. Steady state plasma levels remain constant during prolonged treatment although there is substantial interindividual variation; plasma levels range between 39 and 115 ng/mL.

In 50 elderly patients (mean age 61 years), with intermittent claudication, long term (median 6 months) treatment with flunarizine, 10 mg per day, yielded fairly constant steady state plasma levels albeit with considerable interindividual differences. While plasma flunarizine levels were between 50 ng/mL and 100 ng/mL in 46% of patients, individual values ranged from less than 20 ng/mL to 580 ng/mL. Flunarizine was devoid of cumulative effects as shown by repeated measurements.

As indicated by the large apparent volume of distribution (mean = 43.2 L/kg; range = 26.7 – 79.9 L/kg) seen after the oral administration of 30 mg in healthy volunteers, flunarizine is extensively distributed to tissues. Drug concentrations in tissues, particularly adipose tissue and skeletal muscle, were several times higher than plasma levels.

Flunarizine is 99.1% bound; 90% is bound to plasma proteins and 9% distributed to blood cells, leaving less than 1% present as free drug in the plasma water.

Flunarizine is metabolized principally through N-oxidation and aromatic hydroxylation. During a 48 hour period after a single 30 mg dose, minimal urinary (<0.2%) and fecal (<6%) excretion of flunarizine and/or its metabolites was found. This indicates that the drug and its metabolites are excreted very slowly over a prolonged period of time.

Flunarizine has a long elimination half-life of about 19 days.

Table 1: Pharmacokinetic parameters of flunarizine in healthy volunteers

No. of Doses	Dose (mg)	C _{max} (ng/mL)	T _{max} (h)	AUC (ng/mL·h)	t _{1/2α} (h)	Cl _p (mL/min)	t _{1/2β} (mean days) [range]
Single Dose Studies	5	30.5	2-4	133 ^a	2.4	443.7	4 [2-8]
	10	81.5		615 ^d	2.8		
	20	117.0	1091 ^d	3.6			
	30	81.6	1169 ^a	5			
Multiple Dose Studies	14	5	18.1 ^b	1264 ^d	301.2	[4-19]	19
	14	10	38.8 ^b				
	14	15	68.4 ^b				
	57	10	114.5				

a Area under curve 0 to 8 hours

c Area under curve 0 to 168 hours

b Plasma concentrations at 2 hours

d Area under curve 0 to 24 hours

INDICATIONS AND CLINICAL USE

SIBELIUM (flunarizine hydrochloride) is indicated in the prophylaxis of classic and common migraine. The safety of flunarizine in long-term use (i.e. for more than 4 months) has not been systematically evaluated in controlled clinical trials. Flunarizine is not indicated in the treatment of acute migraine attacks.

CONTRAINDICATIONS

SIBELIUM (flunarizine hydrochloride) is contraindicated in patients with known hypersensitivity to the drug. Flunarizine is contraindicated in patients with a history of depression or pre-existing extrapyramidal disorders.

WARNINGS

Clinical studies indicate that flunarizine treatment, even at recommended doses, can produce motor disturbances in subjects who did not show previous neurological deficits. The clinical symptoms resemble Parkinson's disease, however, they do not improve with antiparkinson medication. Experience to date suggests that in most instances the extrapyramidal symptoms tend to be reversible following discontinuation of flunarizine treatment. It is recommended that patients on flunarizine therapy be followed closely and monitored at regular intervals so that extrapyramidal symptoms may be detected early, and if necessary, treatment discontinued. Clinical studies indicate that flunarizine can, even at recommended doses, precipitate depression, mostly in younger patients.

PRECAUTIONS

Since sedation and/or drowsiness occur in some patients during treatment with SIBELIUM (flunarizine hydrochloride) (see ADVERSE REACTIONS), patients should be cautioned against activities which require alertness or rapid, precise responses (e.g. operating machinery or a motor vehicle) until the response to the drug has been determined.

Use in Pregnancy

To date, there are no data to support the use of flunarizine during pregnancy. It should therefore not be administered to pregnant women unless the anticipated benefits outweigh the potential risks.

Use During Lactation

Studies in lactating dogs have shown that flunarizine is excreted in milk. The concentration of flunarizine in milk is much greater than that in plasma. Breast feeding should therefore be discouraged in women taking flunarizine.

Use in the Elderly

The efficacy of flunarizine in the prophylaxis of migraine has not been established in elderly subjects.

Use in Children

The efficacy of flunarizine in the prophylaxis of migraine has not been established in patients younger than 18 years of age.

Use in Patients with Parkinson's Disease

Flunarizine is contraindicated in patients with pre-existing Parkinson's disease or other extrapyramidal disorders (see CONTRAINDICATIONS). Clinical studies indicate that prolonged flunarizine treatment, even at recommended doses, can produce motor disturbances in elderly subjects who did not show previous neurological deficits. The clinical symptoms resemble Parkinson's disease however, they do not improve with antiparkinson medication. Experience to date suggests that in most instances the extrapyramidal symptoms tend to be reversible following discontinuation of flunarizine treatment. It is recommended that patients on flunarizine therapy be followed closely so that extrapyramidal symptoms may be detected early and if necessary, treatment discontinued.

Use in Depressive Patients

Clinical studies indicate that flunarizine can, even at recommended doses, precipitate depression mostly in younger patients (see CONTRAINDICATIONS).

Endocrine Effects

Galactorrhea has been reported in a few female patients, some of whom were also on oral contraceptives, within the first two months of flunarizine treatment. Discontinuation of flunarizine therapy resolved the galactorrhea in most cases. Flunarizine therapy caused a mild but significant elevation of serum prolactin levels while GH, LH, FSH and TSH levels did not show significant variation. Two cases of menstrual irregularities have been reported.

Drug Interactions

Evidence from therapeutic trials in epileptic patients indicates that whereas flunarizine does not affect the kinetics of phenytoin, carbamazepine and valproic acid, it does decrease the plasma levels of mephenytoin. Furthermore, steady state levels of flunarizine are reduced by coadministration of two or more anticonvulsants. This is considered to be a result of enhanced first pass metabolism of flunarizine as a consequence of liver enzyme induction by the anticonvulsant medications.

In other studies, flunarizine was shown not to affect the anticoagulant effect of warfarin sodium or the hypoglycemic effect of glibenclamide and insulin.

Use in Patients with Impaired Hepatic Function

Flunarizine is metabolized by the liver, therefore care should be exercised when flunarizine is given to patients with compromised liver function.

ADVERSE REACTIONS

In clinical trials with SIBELIUM (flunarizine hydrochloride) migraine patients, drowsiness (also described as sedation or fatigue) as well as weight gain (and/or increased appetite) occurred fairly frequently, in the order of 20 and 15%, respectively. Of 840 migraine patients, 23 (2.7%) and 9 (1.1%) required withdrawal from flunarizine therapy due to drowsiness and weight gain, respectively.

The most serious side effect encountered in migraineurs during clinical trials was depression. Of 840 migraine patients, 11 (1.3%) were withdrawn due to depression. International post-marketing experience suggests that patients between 20 and 54 years of age with a personal or familial history of depression are particularly at risk (see CONTRAINDICATIONS and PRECAUTIONS).

Clinical experience in other indications and epidemiologic surveys suggest that extrapyramidal symptoms may develop during flunarizine therapy. Elderly patients are particularly at risk (see CONTRAINDICATIONS and PRECAUTIONS).

Other side effects encountered in clinical trials for migraine prophylaxis included the following:

- Gastrointestinal: Heartburn, nausea, emesis, gastralgia;
- Central Nervous System: Insomnia and sleep change, anxiety, dizziness/vertigo;
- Miscellaneous: Dry mouth, asthenia, muscle aches, skin rash

SYMPTOMS AND TREATMENT OF OVERDOSE

There has been no experience to date with overdosage of SIBELIUM (flunarizine hydrochloride). Based on the pharmacological properties of the drug, sedation and asthenia may be expected to occur. Treatment should consist of induction of emesis or gastric lavage and supportive measures.

DOSAGE AND ADMINISTRATION

The usual adult dosage of SIBELIUM (flunarizine hydrochloride) 10 mg per day administered in the evening. Patients who experience side effects may be maintained on 5 mg HS.

Duration of Therapy

Clinical experience indicates that the onset of effect of flunarizine is gradual and maximum benefits may not be seen before the patient has completed several weeks of continuous treatment. Therapy therefore should not be discontinued for lack of response before an adequate time period has elapsed, e.g. 6-8 weeks.

DOSAGE FORMS

- Composition: Each red and grey capsule contains 5 mg flunarizine (as hydrochloride).
- Availability: SIBELIUM flunarizine hydrochloride capsules are available in blister packages of 60 capsules.
- Storage: SIBELIUM capsules 5 mg should be stored at or below 25°C, protected from light and moisture.


Product monograph available on request.

REFERENCES

- Martinez-Lage JM. Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. *Cephalalgia* 1988; 8 (Suppl 6): 15-20.
- Amery WK et al. Flunarizine, a calcium entry blocker in migraine prophylaxis. *Headache J* 1985; 25(5): 249-54.
- Sibelium product monograph.
- Compendium of Pharmaceuticals and Specialties, 26th edition, 1991.
- Todd PA; Benfield P. Flunarizine: A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. *Drugs* 1989; 38(4): 481-99.
- Borgers M et al. Selective blockage of Ca²⁺-overload by flunarizine. *Inter Angia* 1984; 3:25-31.



*Trademark



once-a-day SIBELIUM[®] flunarizine

See pages iv and v

Epival[®]

divalproex sodium

THERAPEUTIC CLASSIFICATION Anticonvulsant.

INDICATIONS AND CLINICAL USE Sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal; useful in primary generalized seizures with tonic-clonic manifestations. May also be used adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures.

In accordance with the International Classification of Seizures, simple absence is defined as a very brief clouding of the sensorium or loss of consciousness (lasting usually 2-15 seconds) accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present.

CONTRAINDICATIONS Should not be administered to patients with hepatic disease or significant dysfunction. Contraindicated in patients with known hypersensitivity to the drug.

WARNINGS Hepatic failures resulting in fatalities have occurred in patients receiving valproic acid and its derivatives. These incidences usually have occurred during the first six months of treatment with valproic acid. A recent survey study of valproate use in the United States in nearly 400,000 patients between 1978 and 1984, has shown that children under two years of age who received the drug as part of multiple anticonvulsant therapy were at greatest risk (nearly 20-fold increase) of developing fatal hepatotoxicity. These patients typically had other medical conditions such as congenital metabolic disorders, mental retardation or organic brain disease, in addition to severe seizure disorders. The risk in this age group decreased considerably in patients receiving valproate as monotherapy. Similarly, patients aged 3 to 10 years were at somewhat greater risk if they received multiple anticonvulsants than those who received only valproate. Risk generally declined with increasing age. No deaths have been reported in patients over 10 years of age who received valproate alone.

If Epival is to be used in children two years old or younger, it should be used with extreme caution and as a sole agent. The benefits of seizure control should be weighed against the risk.

Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as loss of seizure control, malaise, weakness, lethargy, anorexia, and vomiting. Patients and parents should be instructed to report such symptoms. Because of the non-specific nature of some of the early signs, hepatotoxicity should be suspected in patients who become unwell, other than through obvious cause, while taking Epival (divalproex sodium).

Liver function tests should be performed prior to therapy and at frequent intervals thereafter especially during the first 6 months. However, physicians should not rely totally on serum biochemistry since these tests may not be abnormal in all instances, but should also consider the results of careful interim medical history and physical examination. Caution should be observed in patients with a prior history of hepatic disease. Patients with various unusual congenital disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease may be at particular risk.

In high-risk patients, it might also be useful to monitor serum fibrinogen and albumin for decrease in concentrations and serum ammonia for increases in concentration. If changes occur, the drug should be discontinued. Dosage should be titrated to and maintained at the lowest dose consistent with optimal seizure control.

The drug should be discontinued immediately in the presence of significant hepatic dysfunction, suspected or apparent. In some cases, hepatic dysfunction has progressed in spite of discontinuation of the drug. The frequency of adverse effects, particularly elevated liver enzymes, may increase with increasing dose. Therefore, the benefit gained by improved seizure control by increasing the dosage must be weighed against the increased incidence of adverse effects sometimes seen at higher dosages.

Use in Pregnancy: According to recent reports in the medical literature, valproic acid may produce teratogenicity in the offspring of women receiving the drug during pregnancy. The incidence of neural tube defects in the fetus may be increased in mothers receiving valproic acid during the first trimester of pregnancy. Based upon a single report, it was estimated that the risk of valproic acid exposed women having children with spina bifida is approximately 1.2%. This risk is similar to that which applies to non-epileptic women who have had children with neural tube defects (anencephaly and spina bifida). Animal studies have demonstrated valproic acid induced teratogenicity, and studies in human females have demonstrated placental transfer of the drug.

Multiple reports in the clinical literature indicate an association between the use of anti-epileptic drugs and an increased incidence of birth defects in children born to epileptic women taking such medication during pregnancy. The incidence of congenital malformations in the general population is regarded to be approximately 2%; in children of treated epileptic women, this incidence may be increased 2- to 3-fold. The increase is largely due to specific defects, e.g. congenital malformations of the heart, cleft lip or palate, and neural tube defects. Nevertheless, the great majority of mothers receiving anti-epileptic medications deliver normal infants.

Data are more extensive with respect to diphenylhydantoin and phenobarbital, but these drugs are also the most commonly prescribed anti-epileptics. Some reports indicate a possible similar association with the use of other anti-epileptic drugs, including trimethadione, paramethadione, and valproic acid. However, the possibility also exists that other factors, e.g. genetic predisposition or the epileptic condition itself may contribute to or may be mainly responsible for the higher incidence of birth defects.

Anti-epileptic drugs should not be discontinued in patients to whom the drug is administered to prevent major seizures, because of the strong possibility of precipitating status epilepticus with attendant hypoxia and risks to both the mother and the unborn child. With regard to drugs given for minor seizures, the risks of discontinuing medication prior to or during pregnancy should be weighed against the risk of congenital defects in the particular case and with the particular family history.

Epileptic women of child-bearing age should be encouraged to seek the counsel of their physician and should report the onset of pregnancy promptly to him. Where the necessity for continued use of anti-epileptic medication is in doubt, appropriate consultation is indicated.

Nursing Mothers: Valproic acid is excreted in breast milk. Concentrations in breast milk have been reported to be 1 to 10% of serum concentrations. As a general rule, nursing should not be undertaken while a patient is receiving Epival (divalproex sodium).

Fertility: Chronic toxicity studies in juvenile and adult rats and dogs demonstrated reduced spermatogenesis and testicular atrophy at doses of valproic acid greater than 200 mg/kg/day in rats and 90 mg/kg/day in dogs. Segment 1 fertility studies in rats have shown that doses up to 350 mg/kg/day for 60 days have no effect on fertility. The effect of divalproex sodium and valproic acid on the development of the testes and on sperm production and fertility in humans is unknown.

LONG-TERM TOXICITY STUDIES IN RATS AND MICE INDICATED A POTENTIAL CARCINOGENIC RISK.

PRECAUTIONS Hepatic dysfunction: See CONTRAINDICATIONS and WARNINGS.

General: Because of reports of thrombocytopenia and inhibition of platelet aggregation, platelet counts and bleeding-time determination are recommended before instituting therapy and at periodic intervals. It is recommended that patients be monitored for platelet count prior to planned surgery. Clinical evidence of hemorrhage, bruising or a disorder of hemostasis/coagulation is an indication for reduction of dosage or withdrawal of therapy pending investigation.

Hyperammonemia with or without lethargy or coma has been reported and may be present in the absence of abnormal liver function tests; if elevation occurs the drug should be discontinued.

Because Epival (divalproex sodium) may interact with other anti-epileptic drugs, periodic serum level determinations of concurrently administered anti-epileptics are recommended during the early part of therapy. (See DRUG INTERACTIONS.) There have been reports of breakthrough seizures occurring with the combination of valproic acid and phenytoin.

Epival (divalproex sodium) is partially eliminated in the urine as a ketone-containing metabolite which may lead to a false interpretation of the urine ketone test.

There have been reports of altered thyroid function tests associated with valproic acid; the clinical significance of these is unknown.

Driving and Hazardous Occupations: May produce CNS depression, especially when combined with another CNS depressant, such as alcohol. Therefore, patients should be advised not to engage in hazardous occupations, such as driving a car or operating dangerous machinery, until it is known that they do not become drowsy from the drug.

Drug Interactions: May potentiate the CNS depressant action of alcohol.

There is evidence that valproic acid may cause an increase in serum phenobarbital levels, by impairment of non-renal clearance. This phenomenon can result in severe CNS depression. The combination of valproic acid and phenobarbital has also been reported to produce CNS depression without significant elevations of barbiturate or valproic acid serum levels. Patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. Serum barbiturate drug levels should be obtained, if possible, and the barbiturate dosage decreased, if indicated.

Primidone is metabolized into a barbiturate, and therefore, may also be involved in a similar or identical interaction.

There is conflicting evidence regarding the interaction of valproic acid with phenytoin (See PRECAUTIONS - General). It is not known if there is a change in unbound (free) phenytoin serum levels. The dosage of phenytoin should be adjusted as required by the clinical situation.

The concomitant use of valproic acid and clonazepam may produce absence status.

ADVERSE REACTIONS The most commonly reported adverse reactions are nausea, vomiting and indigestion. Since valproic acid has usually been used with other anti-epileptics, it is not possible in most cases to determine whether the adverse reactions mentioned in this section are due to valproic acid alone or to the combination of drugs.

Gastrointestinal: Nausea, vomiting and indigestion are the most commonly reported side effects at the initiation of therapy. These effects are usually transient and rarely require discontinuation of therapy. Diarrhea, abdominal cramps and

constipation have also been reported. Anorexia with some weight loss and increased appetite with some weight gain have also been seen.

CNS Effects: Sedative effects have been noted in patients receiving valproic acid alone but are found most often in patients on combination therapy. Sedation usually disappears upon reduction of other anti-epileptic medication. Ataxia, headache, nystagmus, diplopia, asterixis, "spots before the eyes", tremor, dysarthria, dizziness, and incoordination have rarely been noted. Rare cases of coma have been reported in patients receiving valproic acid alone or in conjunction with phenobarbital.

Dermatologic: Transient increases in hair loss have been observed. Skin rash and petechiae have rarely been noted.

Endocrine: There have been reports of irregular menses and secondary amenorrhea in patients receiving valproic acid.

Abnormal thyroid function tests have been reported (See PRECAUTIONS).

Psychiatric: Emotional upset, depression, psychosis, aggression, hyperactivity and behavioural deterioration have been reported.

Musculoskeletal: Weakness has been reported.

Hematopoietic: Thrombocytopenia has been reported. Valproic acid inhibits the second phase of platelet aggregation (See PRECAUTIONS). This may be reflected in altered bleeding time. Bruising, hematoma formation and frank hemorrhage have been reported. Relative lymphocytosis and hypofibrinogenemia have been noted. Leukopenia and eosinophilia have also been reported. Anemia and bone marrow suppression have been reported.

Hepatic: Minor elevations of transaminases (eg. SGOT and SGPT) and LDH are frequent and appear to be dose related. Occasionally, laboratory tests also show increases in serum bilirubin and abnormal changes in other liver function tests. These results may reflect potentially serious hepatotoxicity (See WARNINGS).

Metabolic: Hyperammonemia (See PRECAUTIONS). Hyperglycinemia has been reported and associated with a fatal outcome in a patient with pre-existing non-ketotic hyperglycinemia.

Pancreatic: There have been reports of acute pancreatitis occurring in association with therapy with valproic acid.

Other: Edema of the extremities has been reported.

DOSAGE AND ADMINISTRATION The recommended initial dosage is 15 mg/kg/day, increasing at one week intervals by 5 to 10 mg/kg/day until seizures are controlled or side effects preclude further increases.

The maximal recommended dosage is 60 mg/kg/day. When the total daily dose exceeds 125 mg, it should be given in a divided regimen (See Table).

The frequency of adverse effects (particularly elevated liver enzymes) may increase with increasing dose. Therefore, the benefit gained by improving seizure control must be weighed against the increased incidence of adverse effects.

As the dosage is raised, blood levels of phenobarbital or phenytoin may be affected (See PRECAUTIONS).

Patients who experience G.I. irritation may benefit from administration of the drug with food or by a progressive increase of the dose from an initial low level. The tablets should be swallowed without chewing.

AVAILABILITY Epival (divalproex sodium) enteric-coated tablets are available as salmon-pink coloured tablets of 125 mg; peach-coloured tablets of 250 mg; lavender-coloured tablets of 500 mg. Supplied in bottles of 100 tablets.

Table of Initial Doses by Weight (based on 15 mg/kg/day)

Weight		Total daily dose (mg)	Dosage (mg) Equivalent to valproic acid		
kg	lb		Dose 1	Dose 2	Dose 3
10-24.9	22-54.9	250	125	0	125
25-39.9	55-87.9	500	250	0	250
40-59.9	88-131.9	750	250	250	250
60-74.9	132-164.9	1,000	250	250	500
75-89.9	165-197.9	1,250	500	250	500

Product monograph available on request.

REFERENCES:

1. Wilder BJ. *Epilepsia* 1987;28(suppl. 2):S1-S7.
2. Chadwick DW. *Epilepsia* 1987;28(suppl. 2):S12-S17.
3. Callaghan N et al. *Dev Med and Child Neurol* 1982;24: 830-836.
4. Callaghan N, Kenry RA, O'Neill B et al. *J Neurol Neurosurg Psychiatry* 1985;48:639-644.
5. Dreifuss FE, Langer DH. *Am J Med* 1988;84(suppl. 1A): 34-41.
6. Study F80-118. Abbott Laboratories, Limited.
7. Vining EPG. *Epilepsia* 1987;28(suppl. 2):S18-S22.
8. A Textbook for the Clinical Application of Therapeutic Drug Monitoring. Section 4: Antiepileptic drugs. W Taylor, D Caviness, eds. Abbott Diagnostics, Abbott Park, Ill, 1987.
9. *Drug Interaction Facts*. JB Lippincott, St. Louis, MO, 1990.



EPI/18A01-Jan, 1991 TM Abbott Laboratories Limited

ABBOTT LABORATORIES, LIMITED
P.O. BOX 6150 STATION A
MONTREAL, QUEBEC H3C 3K6

See page xvi

ACTIONS Parlodel (bromocriptine mesylate) is a dopaminomimetic ergot derivative with D₂ type dopamine receptor agonist activity, and has also D₁ dopamine receptor antagonist properties. The dopaminomimetic activity of bromocriptine in the striatum is considered responsible for the clinical benefits seen in selected patients with Parkinson's disease, when low doses of the drug are gradually added to levodopa therapy in patients on long-term treatment who develop late side effects of levodopa or no longer respond to the medication. Excessive dopaminomimetic drive may, however, provoke psychotic and other adverse reactions.

The extreme variability in G.I. tract absorption and the extensive and individually variable first-pass metabolism are responsible for the broad variability in plasma concentrations of bromocriptine and, in part, for the variability in dose response.

INDICATIONS† Parkinson's Disease: Parlodel (bromocriptine mesylate) has been found to be clinically useful as an adjunct to levodopa (usually with a decarboxylase inhibitor), in the symptomatic management of selected patients with Parkinson's disease who experience prominent dyskinesia or wearing off reactions on long-term levodopa therapy.

Patients on long-term treatment who are beginning to deteriorate on levodopa therapy may be controlled by reducing the dose of levodopa and adjusting the frequency and schedule of drug administration. Patients maintained on optimal dosages of levodopa who still experience prominent dyskinesia and/or end-of-dose failure may benefit from the concomitant use of Parlodel, by decreasing the occurrence and/or severity of these manifestations. Since rapid escalation of bromocriptine doses causes severe adverse reactions, it is recommended to combine a slow increase of Parlodel, usually with a concomitant, gradual and limited reduction of levodopa dosage. Continued efficacy of bromocriptine for more than two years has not been established and there is some evidence that its efficacy tends to wane. Evidence available indicates that there is no consistent benefit from bromocriptine in patients who have not responded previously to levodopa, and studies have shown significantly more adverse reactions in bromocriptine-treated patients than in patients treated with levodopa. Parlodel is not recommended in the treatment of newly diagnosed patients or as the sole medication in Parkinson's disease.

CONTRAINDICATIONS Other than sensitivity to ergot alkaloids, no absolute contraindications to treatment with Parlodel (bromocriptine mesylate) are known. For procedure during pregnancy see "Use in Pregnancy" under Precautions.

WARNINGS Long-term treatment (6-36 months) with Parlodel in doses of 20 to 100 mg/day has been associated with pulmonary infiltrates, pleural effusion and thickening of the pleura in a few patients. Where Parlodel was discontinued, these changes slowly reverted to normal.

PRECAUTIONS Parlodel (bromocriptine mesylate) may cause hypotension, primarily postural; periodic monitoring of the blood pressure, particularly during the first days of therapy, is advisable. In some patients dizziness (vertigo) may occur with Parlodel; patients should therefore be cautioned against activities requiring rapid and precise responses, such as driving an automobile or operating dangerous machinery, until their response has been determined.

Care should be exercised when administering Parlodel concomitantly with phenothiazines or antihypertensive agents. Due to drug interaction at the receptor site, dosage should be adjusted accordingly.

Alcohol should be avoided during treatment with Parlodel. In some patients, the concomitant use of Parlodel and alcohol has given rise to alcohol intolerance and an increase in the severity and incidence of Parlodel's possible adverse reactions.

Parlodel should always be taken with food. In cases

where severe adverse effects, such as nausea, vomiting, vertigo or headaches are severe or persisting, the therapeutic dosage of Parlodel should be reduced to half of one tablet daily (1.25 mg) and increased gradually to that recommended. The dopamine antagonist domperidone may be useful in the control of severe gastrointestinal side effects in parkinsonian patients receiving Parlodel (see Drug Interactions).

As with all medication, Parlodel should be kept safely out of the reach of children.

Use in Pregnancy: If the patient wishes to become pregnant, Parlodel (bromocriptine mesylate) should be stopped as soon as possible after conception is suspected. In this event immunological confirmation should be done immediately. When pregnancy is confirmed, Parlodel, like all other drugs, should be discontinued unless, in the opinion of the treating physician, the possible benefit to the patient outweighs the potential risk to the fetus.

In human studies with Parlodel (reviewed by Turkali, I.), there were 1410 reported pregnancies, which yielded 1236 live and 5 stillborn infants from women who took Parlodel (bromocriptine mesylate) during early pregnancy. Among the 1241 infants, 43 cases (31 minor and 12 major) of congenital anomalies were reported. The incidence (3.46%) and type of congenital malformations and the incidence of spontaneous abortions (11.13%) in this group of pregnancies does not exceed that generally reported for such occurrences in the population at large.

Use in Parkinson's Disease: Use of Parlodel (bromocriptine mesylate), particularly in high doses, may be associated with mental confusion and mental disturbances. Since patients with Parkinson's disease may manifest varying degrees of dementia, caution should be exercised when treating such patients with Parlodel.

Parlodel administered alone or concomitantly with levodopa may cause visual or auditory hallucinations. These usually resolve with dosage reduction, but discontinuation of Parlodel may be required in some cases. Rarely, after high doses, hallucinations have persisted for several weeks following discontinuation of Parlodel. Caution should be exercised when administering Parlodel to patients with a history of myocardial infarction, particularly if they have a residual atrial, nodal or ventricular arrhythmia.

Symptomatic hypotension can occur and, therefore, caution should be exercised when administering Parlodel, particularly in patients receiving antihypertensive medication. Periodic evaluation of hepatic, hematopoietic, cardiovascular and renal function is recommended.

Drug Interactions: The concomitant use of erythromycin may increase bromocriptine plasma levels.

Domperidone, a dopamine antagonist, may cause increases in serum prolactin. In so doing, domperidone may antagonise the therapeutically relevant prolactin lowering effect of Parlodel. It is possible that the antitumorigenic effect of Parlodel in patients with prolactinomas may be partially blocked by domperidone administration.

ADVERSE REACTIONS The most frequently observed adverse reactions are nausea, vomiting, headache and gastrointestinal side effects such as abdominal pain, diarrhea and constipation. All these effects may be minimized or even prevented by giving small initial doses of bromocriptine and by taking it with food.

Postural hypotension which can, on rare occasions, lead to fainting and "shock-like" syndromes has been reported in sensitive patients. This is most likely to occur during the first few days of Parlodel treatment.

When bromocriptine is added to levodopa therapy, the incidence of adverse reactions may increase. The most common newly appearing adverse reactions in combination therapy were: nausea, abnormal involuntary movements,

hallucinations, confusion, "on-off" phenomenon, dizziness, drowsiness, faintness, fainting, vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, depression, hypotension, shortness of breath, constipation and vertigo.

Less common adverse reactions include anorexia, anxiety, blepharospasm, dry mouth, dysphagia, edema of the feet and ankles, erythromelalgia, epileptiform seizures, fatigue, headache, lethargia, mottling of skin, nasal stuffiness, nervousness, nightmares, paresthesia, skin rash, urinary frequency, urinary incontinence, urinary retention and rarely signs or symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud's syndrome.

Abnormalities in laboratory tests may include elevation of blood urea nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient and not of clinical significance.

The occurrence of adverse reactions may be lessened by temporarily reducing dosage to one-half tablet two or three times daily.

SYMPTOMS AND TREATMENT OF OVERDOSE There have been several reports of acute overdosage with Parlodel (bromocriptine mesylate) in children and adults. No life threatening reactions have occurred. Symptoms reported included nausea, vomiting, dizziness, drowsiness, hypotension, sweating and hallucinations. Management is largely symptomatic; the cardiovascular system should be monitored. Metoclopramide can be used to antagonize the emesis and hallucinations in patients who have taken high doses.

DOSAGE AND ADMINISTRATION Parlodel (bromocriptine mesylate) should always be taken with food.

Although Parlodel (bromocriptine mesylate) has been found clinically useful in decreasing the severity and frequency of "on-off" fluctuations of late levodopa therapy, the decision to use bromocriptine as adjunctive treatment and the selection of dosage must be individualized in each case. A low dose is recommended. The initial dose of Parlodel is one half of a 2.5 mg tablet (1.25 mg) at bedtime with food to establish initial tolerance. Thereafter, the recommended dosage is 2.5 mg daily in two divided doses, with meals, (half a 2.5 mg tablet twice daily). The dosage may be increased very gradually, if necessary, by adding an additional 2.5 mg per day, once every 2 to 4 weeks, to be taken always in divided doses with meals. Increments should usually not exceed 2.5 mg. Clinical assessments are recommended at two week intervals or less during dosage titration, to ensure that the lowest effective dosage is not exceeded. The usual dosage range is from a few milligrams to 40 mg daily in two or three divided doses with meals. The median dose varies with the experience of individual investigators, but can be around 10 mg daily or higher. During initial titration it is recommended that the dosage of levodopa should be maintained, if possible. Subsequently, it might be desirable to combine a slow increase of bromocriptine with a concomitant, limited and gradual reduction of levodopa.

AVAILABILITY

TABLETS each containing 2.5 mg bromocriptine, as mesylate, available in bottles of 100.
CAPSULES each containing 5 mg bromocriptine, as mesylate, available in bottles of 100.

[†]For information on other approved indications, please consult the Parlodel Product Monograph, available to physicians and pharmacists on request.

*Registered trademark

PAAB

SANDOZ SANDOZ CANADA INC.
Dorval Quebec H9R 4P5

See IFC

Intermediate Prescribing Information

TEGRETOL® (carbamazepine tablets)

TEGRETOL® 200 mg

TEGRETOL® Chewtabs

(carbamazepine chewable tablets)

TEGRETOL® Chewtabs™ 100 mg

TEGRETOL® Chewtabs™ 200 mg

TEGRETOL® CR

(carbamazepine controlled release tablets)

TEGRETOL® CR 200 mg TEGRETOL® CR 400 mg

Anticonvulsant

For symptomatic relief of trigeminal neuralgia

INDICATIONS Symptomatic relief of pain of true or primary trigeminal neuralgia (tic douloureux). Not for prophylactic use. Glossopharyngeal neuralgia has been relieved in some patients. Other measures must be considered for patients failing to respond or who are sensitive to TEGRETOL. Management of psychomotor (temporal lobe) epilepsy. As an adjunct in some patients with secondary or partial epilepsy with complex symptomatology or secondarily generalized seizures, when combined with other antiepileptic agents. As an alternative in patients with generalized tonic-clonic seizures and marked side effects or who fail to respond to other anticonvulsant drugs. Ineffective for controlling petit mal, minor motor, myoclonic and predominantly unilateral seizures, and does not prevent generalization of epileptic discharge. Exacerbation of seizures may occur in patients with atypical absences.

CONTRAINDICATIONS History of hepatic disease, acute intermittent porphyria or serious blood disorder, in patients with AV heart block (see Precautions), hypersensitivity to carbamazepine or to tricyclic compounds, or their analogues or metabolites. Do not give with, immediately before or immediately after treatment with monamine oxidase inhibitors. There should be as long a drug free interval as the clinical condition allows, in no case less than 14 days. Then TEGRETOL dosage should be low initially, increased very gradually.

WARNINGS Although reported infrequently, serious adverse effects have been observed during use of TEGRETOL (carbamazepine). **Agranulocytosis and aplastic anemia have occurred in a few instances with a fatal outcome. Leucopenia, thrombocytopenia, hepatocellular and cholestatic jaundice, and hepatitis also reported. It is therefore important that TEGRETOL be used carefully and close clinical and frequent laboratory supervision be maintained throughout treatment to detect signs and symptoms of possible blood dyscrasia, as early as possible. Discontinue TEGRETOL if any evidence of significant bone marrow depression appears. (See "Precautions.")** Should signs and symptoms suggest a severe skin reaction such as Steven-Johnson syndrome or Lyell's syndrome, withdraw TEGRETOL at once. Long-term toxicity studies in rats indicated a potential carcinogenic risk. Therefore possible risk of the drug must be weighed against potential benefits before prescribing TEGRETOL. **Pregnancy and nursing:** Women with epilepsy who are, or intend to become pregnant, should be treated with special care. In women of childbearing potential, TEGRETOL (carbamazepine) should, whenever possible, be prescribed as monotherapy, because the incidence of congenital abnormalities in offspring of women treated with more than one antiepileptic drug is greater than in those receiving single antiepileptic. Minimum effective doses should be given and plasma levels monitored. If woman receiving TEGRETOL becomes pregnant, or if the problem of initiating TEGRETOL arises during pregnancy, weigh the drug's potential benefits against its hazards, particularly during the first 3 months of pregnancy. Do not discontinue TEGRETOL or withhold from patients if required to prevent major seizures because of the risks posed, to both mother and fetus, by status epilepticus with attendant hypoxia. Possibility that carbamazepine, like all major antiepileptic drugs, increases the risk of malformations, including spina bifida, in association with carbamazepine. Conclusive evidence from controlled studies with carbamazepine monotherapy is lacking. Folic acid deficiency is known to occur in pregnancy. Antiepileptic drugs have been reported to aggravate folic acid deficiency, which may contribute to increased incidence of birth defects in offspring of treated epileptic women. Folic acid supplementation is recommended before and during pregnancy. Vitamin K₁ administration to mother during last weeks of pregnancy, and to newborn, has been recommended to prevent neonatal bleeding disorders. Carbamazepine passes into breast milk in concentrations of about 25-60% of the plasma level. No reports available on long-term effect of breast feeding. Weigh benefits of breast feeding against possible risks to infant. Observe infant for possible adverse reactions, e.g. somnolence, should mother taking carbamazepine nurse her infant. A severe hypersensitivity skin reaction in a breast-fed baby has been reported. Reliability of oral contraceptives may be adversely affected by carbamazepine (see Precautions, Drug Interactions).

PRECAUTIONS **Clinical Monitoring of Adverse Reactions:** Prescribe TEGRETOL only after a critical risk-benefit appraisal in patients with a history of cardiac, hepatic or renal damage, adverse haematological reactions to other drugs, or interrupted courses of therapy with TEGRETOL. **Maintain careful clinical and laboratory supervision throughout treatment.** Should any signs or symptoms or abnormal laboratory findings be suggestive of blood dyscrasia or liver disorder, discontinue TEGRETOL immediately until case is carefully reassessed. (a) **Bone marrow function:** Carry out complete blood counts, including platelets and possibly reticulocytes and serum iron, before treatment is instituted. Suggested guidelines for monitoring are weekly for the first month, monthly for the next 5 months, thereafter 2-4 times/year. If definitely low or decreased white blood cell or platelet counts are observed during treatment, patient and complete blood count should be monitored closely. Non-progressive fluctuating asymptomatic leucopenia encountered, does not generally call for TEGRETOL withdrawal. However, treatment should be discontinued if the patient develops leucopenia which is progressive or accompanied by clinical manifestations, e.g. fever or sore throat, which could indicate onset of significant bone marrow depression. **Because onset of potentially serious blood dyscrasias may be rapid, patients should be made aware of early toxic signs and symptoms of potential hematological problem, and symptoms of dermatological or hepatic reactions.** If reactions, e.g. fever, sore throat, rash, ulcers in mouth, easy bruising, petechial or purpuric hemorrhage appear, advise patient to consult his/her physician immediately. (b) **Hepatic function:** Baseline and periodic evaluations of hepatic function must be performed, particularly in elderly patients and those with history of liver disease. Withdraw TEGRETOL immediately in cases of aggravated liver dysfunction or active liver disease. (c) **Kidney function:** Perform pretreatment and periodic complete urinalysis and BUN determinations. (d) **Ophthalmic examinations:** Carbamazepine has been associated with pathological eye changes. Periodic eye examinations, including slit-lamp funduscopy and tonometry recommended. (e) **Plasma levels:** Although correlations between dosage and plasma levels of carbamazepine, and between plasma levels and clinical efficacy or tolerability are rather tenuous, monitoring plasma levels may be useful in the following conditions: dramatic increase in seizure frequency/verification of patient compliance; pregnancy; when treating children or adolescents; suspected absorption disorders; suspected toxicity, especially where more than one drug is being used (see "Interactions"). **Increased seizure frequency:** Use TEGRETOL with caution in patients with mixed seizure disorder that includes atypical absence seizures, since use has been associated with increased frequency of generalized convulsions. In case of exacerbation of seizures, discontinue TEGRETOL. **Dermatologic:** Mild skin reactions, e.g.

isolated macular or maculopapular exanthema, usually disappear within a few days or weeks, either during continued course of treatment or following dosage decrease. However, patient should be kept under close surveillance because of rare possibility of Steven-Johnson syndrome or Lyell's syndrome occurring (see WARNINGS). **Urinary Retention and Increased Intraocular Pressure:** Because of its anticholinergic action, carbamazepine should be given cautiously, if at all, to patients with increased intraocular pressure or urinary retention. Follow such patients closely while on the drug. **Occurrence of Behavioral Disorders:** Because it is closely related to other tricyclic drugs, there is some possibility that carbamazepine might activate latent psychosis, or, in elderly patients, produce agitation or confusion, especially when combined with other drugs. Exercise caution in alcoholics. **Use in Patients with Cardiovascular Disorders:** Use TEGRETOL cautiously in patients with history of coronary artery disease, organic heart disease, or congestive failure. If defective conductive system suspected, perform an ECG before administering TEGRETOL, to exclude patients with atrioventricular block. **Driving and Operating Hazardous Machinery:** Because dizziness and drowsiness are possible side effects of TEGRETOL, warn patients about possible hazards of operating machinery or driving automobiles. **Drug Interactions:** Induction of hepatic enzymes in response to carbamazepine may diminish or abolish activity of certain drugs also metabolized in the liver. Dosage of the following drugs may have to be adjusted: clobazam, clonazepam, ethosuximide, primidone, valproic acid, alprazolam, corticosteroids (e.g. prednisolone, dexamethasone), cyclosporin, digoxin, dicyclanil, felodipine, haloperidol, thioridazine, imipramine, methadone, oral contraceptives, theophylline, and oral anticoagulants (warfarin, phenprocoumon, dicumarol). Phenytoin plasma levels reported to be both raised and lowered by carbamazepine, and mephenytoin plasma levels reported to increase in rare instances. The following drugs have been shown to raise plasma carbamazepine levels: erythromycin, troleandomycin, possibly josamycin, isoniazid, verapamil, diltiazem, propoxyphene, viloxazine, fluoxetine, cimetidine, acetazolamide, danazol, and possibly desipramine. Nicotinamide raises carbamazepine plasma levels in children, but only at high dosage in adults. Since an increase in carbamazepine plasma levels may result in unwanted effects (e.g. dizziness, drowsiness, ataxia, diplopia and nystagmus), adjust TEGRETOL dosage accordingly and monitor the blood levels. Plasma levels of carbamazepine may be reduced by phenobarbitone, phenytoin, primidone, progabide, or theophylline, and possibly by clonazepam. Alternatively, valproic acid, valpromide, and primidone have been reported to raise plasma levels of pharmacologically active metabolite, carbamazepine-10,11 epoxide. TEGRETOL dose may consequently require adjustment. Combined use with lithium, meprobamate, or haloperidol, may increase risk of neurotoxic side effects (even in presence of "therapeutic plasma levels"). Concomitant use with isoniazid reported to increase isoniazid-induced hepatotoxicity. TEGRETOL, like other anticonvulsants, may adversely affect the reliability of oral contraceptives; breakthrough bleeding may occur. Patients should accordingly be advised to use some alternative, non-hormonal method of contraception. Concomitant medication with TEGRETOL and some diuretics (hydrochlorothiazide, furosemide) may lead to symptomatic hyponatremia. TEGRETOL may antagonize effects of non-depolarising muscle relaxants (e.g. pancuronium); their dosage may need to be raised and patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected. Isotretinoin reported to alter the bioavailability and/or clearance of carbamazepine and its active 10,11-epoxide; carbamazepine plasma levels should be monitored. Carbamazepine may reduce the patient's alcohol tolerance; advisable to abstain from alcohol consumption during treatment. TEGRETOL should not be administered in conjunction with MAO inhibitor (see CONTRAINDICATIONS).

ADVERSE REACTIONS Reactions most frequently reported are CNS (e.g. drowsiness, headache, unsteadiness on feet, diplopia, dizziness), gastrointestinal disturbances (nausea, vomiting), and allergic skin reactions. These reactions usually occur only during the initial phase of therapy. If initial dose is too high, or when treating elderly patients. They have rarely necessitated discontinuing TEGRETOL therapy, and can be minimized by initiating treatment at low dosage. Occurrence of CNS adverse reactions may be manifestation of relative overdose or significant fluctuation in plasma levels. In such cases it is advisable to monitor plasma levels and possibly lower daily dose and/or divide it into 3-4 fractional doses. More serious adverse reactions observed are hematologic, hepatic, cardiovascular and dermatologic reactions, which require discontinuation of therapy. If treatment is to be withdrawn abruptly, effect the change-over to another antiepileptic under cover of diazepam. Adverse reactions reported: **Hematologic:** Occasional or frequent - leucopenia; occasional - eosinophilia, thrombocytopenia; rare - leucocytosis, lymphadenopathy; isolated cases - agranulocytosis, aplastic anemia, pure red cell aplasia, macrocytic anemia, acute intermittent porphyria, reticulocytosis, folic acid deficiency, thrombocytopenic purpura, and possibly hemolytic anemia. In few instances, deaths occurred. **Hepatic:** frequent - elevated gamma-GT (due to hepatic enzyme induction), usually not clinically relevant; occasional - elevated alkaline phosphatase; rarely - transaminases; rare - jaundice, hepatitis of cholestatic, pharyngomal, hepatocellular, or mixed type; isolated cases - granulomatous hepatitis. **Dermatologic:** occasional to frequent - skin sensitivity reactions and rashes, erythematous rashes, urticaria; rare - exfoliative dermatitis and erythroderma, Steven-Johnson syndrome, systemic lupus erythematosus-like syndrome; isolated cases - toxic epidermal necrolysis (Lyell's syndrome), photosensitivity, erythema multiforme and nodosum, skin pigmentation changes, pruritus, purpura, acne, diaphoresis, alopecia and neurodermatitis. **Neurologic:** frequent - vertigo, somnolence, ataxia and fatigue. Occasionally - an increase in motor seizures (see INDICATIONS), headache, diplopia, nystagmus, accommodation disorders (e.g. blurred vision); rare - abnormal involuntary disorders (e.g. tremor, asterix, orofacial dyskinesia, choreoathetosis disorders, dystonia, tics); isolated cases - oculomotor disturbances, speech disorders (e.g. dysarthria or slurred speech), peripheral neuritis, paraesthesiae. There have been some reports of paralysis and other symptoms of cerebral arterial insufficiency but no conclusive relationship to the administration of TEGRETOL could be established. **Cardiovascular:** Disturbances of cardiac conduction, bradycardia, arrhythmias, Stokes-Adams in patients with AV-block, congestive heart failure, hypertension or hypotension, aggravation of coronary artery disease, thrombophlebitis, thromboembolism. Some of these complications (including myocardial infarction and arrhythmia) have been associated with other tricyclic compounds. **Psychiatric:** Isolated cases - hallucinations (visual or acoustic), depression, sometimes with talkativeness, agitation, loss of appetite, restlessness, aggressive behaviour, confusion, activation of psychosis. **Genitourinary:** Isolated cases - interstitial nephritis and renal failure, as well as signs of renal dysfunction (e.g. albuminuria, glycosuria, hematuria, oliguria sometimes associated with elevated blood pressure, and elevated BUN/azotemia), urinary frequency, urinary retention, and renal failure. Isolated reports - sexual disturbances/impotence. **Gastrointestinal:** Occasional or frequent - nausea, vomiting. Occasional: dryness of the mouth and throat; rare - diarrhoea or constipation; isolated cases - abdominal pain, glossitis, stomatitis, anorexia. **Sense organs:** Isolated cases - lens opacities, conjunctivitis, retinal changes, tinnitus, hyperacusis, and taste disturbances. **Endocrine system and metabolism:** Occasionally edema, fluid retention, weight increase, hyponatremia and reduced plasma osmolality due to antidiuretic hormone (ADH)-like effect occurs, leading in isolated cases to water intoxication accompanied by lethargy, vomiting, headache, mental confusion, neurological abnormalities. Isolated cases of gynecomastia or galactorrhea have been reported, as well as abnormal thyroid function tests (decreased L-thyroxine i.e. FT₄, T₄, and increased TSH, usually without clinical manifestations), disturbances of bone metabolism (decrease in plasma calcium and 25-OH-calciferol), leading in isolated cases to osteomalacia, as well as reports of elevated levels of cholesterol, including HDL cholesterol and

triglycerides. **Musculoskeletal system:** Isolated cases - arthralgia, muscle pain or cramp. **Respiratory:** Isolated cases - pulmonary hypersensitivity characterized by fever, dyspnea, pneumonitis or pneumonia. **Hypersensitivity reactions:** Rare delayed multi-organ hypersensitivity disorder with fever, skin rashes, vasculitis, lymphadenopathy, disorders mimicking lymphoma, arthralgia, leucopenia, eosinophilia, hepato-splenomegaly and abnormal liver function tests, occurring in various combinations. Other organs may also be affected (e.g. lungs, kidneys, pancreas, myocardium). Isolated cases: aseptic meningitis, with myoclonus and eosinophilia; anaphylactic reaction. Treatment should be discontinued should such hypersensitivity reactions occur.

SYMPTOMS AND TREATMENT OF OVERDOSAGE Lowest known lethal dose: estimated 3.2g (24 year old woman). Highest known doses survived: 80g (34 year old man); 34g (13 year old girl); 1.4g (23 month old girl). **Symptoms of Overdosage:** The presenting signs and symptoms of overdose usually involve the central nervous, cardiovascular, and respiratory systems. Central nervous system: CNS depression, disorientation, tremor, restlessness, somnolence, agitation, hallucination, coma, blurred vision, nystagmus, mydriasis, slurred speech, dysarthria, ataxia, dyskinesia, abnormal reflexes (slowed/hyperactive), convulsions, psychomotor disturbances, myoclonus, opisthotonus, hyperthermia/hyperthermia, flushed skin/cyanosis, EEG changes. Respiratory system: respiratory depression, pulmonary edema. Cardiovascular system: tachycardia, hypotension/hypertension, conduction disturbance with widening of QRS complex, syncope in association with cardiac arrest. Gastrointestinal system: nausea, vomiting, delayed gastric emptying, reduced bowel motility. Renal function: urinary retention, oliguria or anuria; fluid retention, and water intoxication. Laboratory findings: hyponatremia, hypokalemia, leukocytosis, reduced white cell count, metabolic acidosis, hyperglycemia, glycosuria, acetonuria, increased muscle creatinine phosphokinase. **Treatment of Overdosage:** There is no known specific antidote to TEGRETOL (carbamazepine). Evacuate the stomach, with an emetic or by gastric lavage, then administer activated charcoal. Observe vital signs and administer symptomatic treatment as required. Hyperirritability or convulsions may be controlled by the administration of parenteral diazepam or barbiturates but they may induce respiratory depression, particularly in children. Paraldehyde may be used to counteract muscular hyper-tonus without producing respiratory depression. When barbiturates are employed, it is advisable to have equipment available for artificial ventilation and resuscitation. Barbiturates should not be used if drugs that inhibit monoamine oxidase have been taken by the patient, either in overdose or in recent therapy (within two weeks). Hyponatremia should be treated by restricting fluids and a slow and careful NaCl 0.9% infusion i.v. These measures may be useful in preventing brain damage. Shock (circulatory collapse) should be treated with supportive measures, including intravenous fluids, oxygen, and corticosteroids. For hypotension unresponsive to measures taken to increase plasma volume, dopamine or dobutamine i.v. may be administered. It is recommended that ECG be monitored, particularly in children, to detect cardiac arrhythmias or conduction defects. Charcoal hemoperfusion has been recommended. Forced diuresis, hemodialysis, and peritoneal dialysis reported to be ineffective. Relapse and aggravation of the symptomatology on the 2nd or 3rd day after overdose, due to delayed absorption, should be anticipated.

DOSEAGE AND ADMINISTRATION Use in Epilepsy (See INDICATIONS): Low initial daily dosage of TEGRETOL (carbamazepine) with a gradual increase in dosage is advised. Adjust dosage to the needs of the individual patient. TEGRETOL tablets and CHEWTABS should be taken in 2 to 4 divided doses daily, with meals when possible. Controlled release characteristics of TEGRETOL CR tablets the daily fluctuations of plasma carbamazepine. TEGRETOL CR tablets (either whole or, if so prescribed, half a tablet) should be swallowed unchewed with a little liquid during or after a meal. Controlled release tablets should be prescribed as a b.i.d. dosage. If necessary, 3 divided doses may be prescribed. **Adults and Children Over 12 Years:** Initially, 100 to 200 mg once or twice a day depending on the severity of the case and previous therapeutic history. Initial dosage is progressively increased, in divided doses, until best response is obtained. Usual optimal dosage is 800 to 1200 mg daily. In rare instances some adult patients have received 1600 mg. As soon as disappearance of seizures has been obtained and maintained, reduce dosage very gradually until reaching minimum effective dose. **Children 6-12 Years:** Initially, 100 mg in divided doses on first day. Increase gradually by adding 100 mg/day until best response is obtained. Dosage should generally not exceed 1000 mg daily. As soon as disappearance of seizures has been obtained and maintained, reduce dosage very gradually until reaching minimum effective dose. **Use in Trigeminal Neuralgia:** Initial daily dosage 200 mg taken in 2 doses of 100 mg is recommended. Total daily dosage can be increased by 200 mg/day until relief of pain is obtained, usually achieved at dosage 200-800 mg daily; occasionally up to 1200 mg/day necessary. As soon as relief of pain has been obtained and maintained, attempt progressive reduction in dosage until reaching minimal effective dosage. Because trigeminal neuralgia is characterized by periods of remission, attempts should be made to reduce or discontinue the use of TEGRETOL at intervals of not more than 3 months, depending on individual clinical course. Prophylactic use in trigeminal neuralgia is not recommended.

AVAILABILITY TEGRETOL Tablets 200 mg: Each white, round, flat, bevelled-edge, double-scored tablet engraved GEIGY on one side contains 200 mg carbamazepine. Protect from heat (store below 30°C) and humidity. Bottles of 100 and 500. **TEGRETOL CHEWTABS 100 mg:** Pale pink, round, flat, bevelled-edge tablets with distinct red spots. GEIGY engraved on one side and MR on the other. Fully bisected between the P and R. Each contains 100 mg carbamazepine. Protect from heat (store below 30°C), light and humidity. Bottles of 100. **TEGRETOL CHEWTABS 200 mg:** Pale pink, oval, biconvex tablets with distinct red spots. GEIGY engraved on one side and PU on the other. Fully bisected between the P and U. Each contains 200 mg carbamazepine. Protect from heat (store below 30°C), light and humidity. Bottles of 100. **TEGRETOL CR 200 mg:** Beige-orange, oval, slightly biconvex tablet, engraved CG on one side and HC on the other. Fully bisected on both sides. Each contains 200 mg carbamazepine. Protect from heat (store below 25°C) and humidity. Bottles of 100. **TEGRETOL CR 400 mg:** Brownish-orange, oval, slightly biconvex tablet, engraved CG/CG on one side and ENE/ENE on the other. Fully bisected on both sides. Each contains 400 mg carbamazepine. Protect from heat (store below 25°C) and humidity. Bottles of 100. TEGRETOL is available to patients only by prescription. Product Monograph available upon request.

REFERENCES 1. Smith DB, et al: Results of a nationwide Veterans Administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. *Epilepsia* 1997; 28(Suppl 3): 550-558. 2. Trimble MR: Anticonvulsant drugs and cognitive function: a review of the literature. *Epilepsia* 1987; 28(Suppl 3): 537-545. 3. Dooley JM: Seizures in childhood. *Medicine North America* 1989; 4th series 2: 163-172. 4. Reynolds EH: Polytherapy, monotherapy, and carbamazepine. *Epilepsia* 1987; 28(Suppl 3): 577-580. 5. Aldenkamp AP, et al: Controlled release carbamazepine: cognitive side effects in patients with epilepsy. *Epilepsia* 1987; 28(5): 507-514. 6. Canger R, et al: Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. *Acta Neurol Scand* 1990; 82: 9-13.

Geigy

Pharmaceuticals Division of
CIBA-GEIGY CANADA LTD.
Mississauga, Ontario L5N 2W5
or
Dorval, Quebec H9S 1B1



6-92711

ACADEMIC APPOINTMENT NEUROSURGEON — ONTARIO

Queen's University, Department of Surgery, geographic full-time position in Neurosurgery commencing as soon as possible. Applicants should be licensed to practise in Ontario and be fellows of the Royal College of Physicians and Surgeons of Canada. The successful candidate will be expected to teach at undergraduate and post-graduate levels and engage in research. He/she will be expected to take a proportion of emergency calls. Salary, ceiling and academic rank will be by negotiation according to qualifications and experience.

Closing date for application is December 31, 1992.

In accordance with Canadian Immigration requirements, this advertisement is directed to Canadian citizens and permanent residents.

Queen's University has an employment equity program, welcomes diversity in the workplace and encourages applications from all qualified candidates, including women, aboriginal peoples, people with disabilities and visible minorities.

Applications with a curriculum vitae and the names of three referees should be sent to Dr. Charles Sorbie, Head, Department of Surgery, Queen's University, Kingston, Ontario K7L 3N6.

Academic Epileptologist and a Neuromuscular Neurologist

Expertise in EEG and epilepsy or nerve or muscle disease sought for two faculty positions at The Toronto Hospital and the University of Toronto. Ability to conduct a research program is desirable.

In accordance with Canadian immigration requirements, this advertisement is directed to Canadian citizens and permanent residents.

Applicants should be eligible for certification in Neurology by the Royal College of Physicians and Surgeons of Canada.

Please send curriculum vitae and letter of application to:

Dr. James A. Sharpe
Professor and Chairman of Neurology
University of Toronto, The Toronto Hospital
399 Bathurst Street
Toronto, Ontario M5T 2S8.



Pediatric Neurosurgeon

The Alberta Children's Hospital is the principle teaching and referral facility for Pediatrics in Southern Alberta. With a staff of 1400, the Centre offers a comprehensive range of inpatient, ambulatory and outreach services, and is affiliated with the University of Calgary Medical School.

This position requires a candidate with excellent clinical, teaching and research skills. The Division of Neurosurgery is affiliated with the Department of Clinical Neurosciences at the University of Calgary. Teaching undergraduate and post-graduate students will be expected. Superior clinical skills are required for both inpatient and ambulatory care services.

Candidates should be eligible for certification by the Royal College of Physicians and Surgeons of Canada and for licensure by the College and Physicians and Surgeons of Alberta.

Qualified persons are invited to submit their curriculum vitae to:

ALBERTA CHILDREN'S HOSPITAL

Dr. S.T. Myles
Chief of Staff - Surgery
1820 Richmond Road S.W.
Calgary, Alberta, Canada T2T 5C7

The Hospital is a smoke-free environment.



NEUROSURGEON

The Department of Surgery, Faculty of Medicine, University of Manitoba and the Health Sciences Centre are seeking a contingent geographical full-time Neurosurgeon.

Candidates must have Senior Specialty qualifications in neurosurgery in the country of current practice and must be eligible for registration with the College of Physicians and Surgeons of Manitoba. Eligibility for, or certification in, Neurosurgery by the Royal College of Physicians and Surgeons of Canada is required.

Specific requirements include the following:

Commitment to Academic Neurosurgery in the provision of exemplary advanced neurosurgical care, research, and residency training.

Salary and academic rank will be commensurate with experience and qualifications.

The University of Manitoba encourages applications from qualified women and men, including members of visible minorities, aboriginal people, and persons with disabilities. The University provides a smoke free work environment save for specially designated areas. In accordance with Canadian Immigration requirements, this advertisement is directed to Canadian citizens and permanent residents.

Applications will be accepted until the position is filled. Interested candidates should apply, enclosing a curriculum vitae in writing to: Dr. R.J.W. Blanchard, Professor & Head, Department of Surgery, Health Sciences Centre, GC411-820 Sherbrook St., Winnipeg, Manitoba, CANADA R3A 1R9.

FELLOWSHIP NEUROSURGICAL ONCOLOGY

The Neurosurgery division of Memorial Sloan Kettering Cancer Center is offering a one or two year fellowship beginning July, 1993. Neurosurgeons or neurosurgeons-in-training interested in neurosurgical oncology and related research are invited to apply.

A wealth of patients with primary and metastatic tumours of the brain and spine provide a unique opportunity for experience in comprehensive management and clinical research.

Participation in a variety of basic research projects is offered and encouraged.

Reply to:

Joseph H. Galicich, M.D.
Neurosurgery Service
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10021

AN EQUAL OPPORTUNITY EMPLOYER

CLINICAL FELLOW IN NEUROSURGERY

Applications are invited for the position of clinical fellow in neurosurgery, Memorial University of Newfoundland. The post becomes vacant December 1, 1992 and is for a period of one year (renewable). The Provincial Neurosurgery Unit is based at the Health Sciences Centre. Previous experience in neurosurgery and the Medical Council of Canada Evaluating Examination is required. Salary — \$47,418.

In accordance with Canadian Immigration requirements, this advertisement is directed to Canadian citizens and permanent residents. Closing date for this advertisement is November 30, 1992.

For further information contact:

Dr. F.B. Maroun, Acting Chairman
Discipline of Surgery
Memorial University of Newfoundland
Health Sciences Centre
St. John's, NF A1B 3V6

*Memorial University is committed to
employment equity.*



THE DR. CHARLES A. JANEWAY CHILD HEALTH CENTRE

PEDIATRIC NEUROLOGIST

The Janeway Child Health Centre and Memorial University of Newfoundland invite applications for a position in clinical pediatric neurology. The Janeway is a 149-bed facility that serves as the tertiary level pediatric referral centre of Newfoundland and Labrador. Opportunity exists for an appointment in the Discipline of Pediatrics at Memorial University with ample opportunity for research and teaching.

Applicants should hold the FRCP (C) qualification and be eligible for medical licensure in Newfoundland. Applications and inquiries should be directed to:

DR. A.J. DAVIS
Chief of Pediatrics
The Dr. Charles A. Janeway Child Health Centre
Janeway Place
St. John's, Newfoundland A1A 1R8

PROLOPA® 50/12.5

levodopa 50 mg benserazide 12.5 mg

Rx Summary

Antiparkinsonian Agent

Indications

Treatment of Parkinson's syndrome when not drug induced.

Contraindications

Known hypersensitivity to levodopa or benserazide; in patients in whom sympathomimetic amines are contraindicated; concomitantly with, or within 2 weeks of, MAOI administration; uncompensated cardiovascular, endocrine, renal, hepatic, hematologic or pulmonary disease; narrow-angle glaucoma.

Warnings

Discontinue levodopa at least 12 hours before initiating

'Prolopa'. See Dosage section for substitution recommendations.

Not indicated in intention tremor, Huntington's chorea or drug-induced Parkinsonism.

Increase dosage gradually to avoid CNS side effects (involuntary movements). Observe patients for signs of depression with suicidal tendencies or other serious behavioural changes. Caution in patients with history of psychotic disorders or receiving psychotherapeutic agents.

In patients with atrial, nodal or ventricular arrhythmias or history of myocardial infarction initiate treatment cautiously in hospital. Caution in patients with history of melanoma or suspicious undiagnosed skin lesions. Safety in patients under 18 years has not been established. In women who are or may become pregnant, weigh benefits against possible hazards to mother and fetus. Not recommended for nursing mothers.

Precautions

Monitor cardiovascular, hepatic, hematopoietic and renal function during extended therapy. Caution in patients with history of convulsive disorders. Upper gastrointestinal hemorrhage possible in patients with a history of peptic ulcer.

Normal activity should be resumed gradually to avoid risk of injury.

Monitor intraocular pressure in patients with chronic wide-angle glaucoma. Pupillary dilation and activation of Horner's syndrome have been reported rarely. Exercise caution and monitor blood pressure in patients on anti-hypertensive medication. 'Prolopa' can be discontinued 12 hours prior to anesthesia. Observe patients on concomitant psychoactive drugs for unusual reactions.

Adverse Reactions

Most common are abnormal involuntary movements, usually dose dependent, which necessitate dosage reduction. Other serious reactions are periodic oscillations in performance (end of dose akinesia, on-off phenomena and akinesia paradoxa) after prolonged therapy, psychiatric disturbances (including paranoia, psychosis, depression, dementia, increased libido, euphoria, sedation and stimulation), and cardiovascular effects (including arrhythmias, orthostatic hypotension, hypertension, ECG changes and angina pectoris).

Neurologic, intellectual, gastrointestinal, dermatologic, hematologic, musculoskeletal, respiratory, genitourinary and ophthalmologic reactions have also been reported. Consult Product Monograph for complete list.

Dosage

Individualize therapy and titrate in small steps to maximize benefit without dyskinesias. Do not exceed the recommended dosage range.

Initially, one capsule 'Prolopa' 100-25 once or twice daily, increased carefully by one capsule every third or fourth day (slower in post-encephalitic Parkinsonism) until optimum therapeutic effect obtained without dyskinesias. At upper limits of dosage, increment slowly at 2-4 week intervals. Administer with food.

Optimal dosage is usually 4-8 'Prolopa' 100-25 capsules daily, in 4-6 divided doses.

'Prolopa' 200-50 capsules are intended for maintenance therapy once optimal dosage has been determined using 'Prolopa' 100-25 capsules. No patient should receive more than 1000-1200 mg levodopa daily during the first year of treatment. 'Prolopa' 50-12.5 capsules should be used when frequent dosing is required to minimize adverse effects.

For patients previously treated with levodopa, allow at least 12 hours to elapse and initiate 'Prolopa' at 15% of previous levodopa dosage.

During maintenance, reduce dosage slowly, if possible, to a maximum of 600 mg levodopa daily.

Supply

'Prolopa' 50-12.5 capsules containing 50 mg levodopa and 12.5 mg benserazide. Contains mannitol.

'Prolopa' 100-25 capsules containing 100 mg levodopa and 25 mg benserazide.

'Prolopa' 200-50 capsules containing 200 mg levodopa and 50 mg benserazide.

Bottles of 100

Product Monograph available on request.

References

1. Da Prada, M. (1984). Peripheral decarboxylase inhibition: a biochemical comparison between benserazide and carbidopa. *Parkinson's Disease: Actual Problems and Management*. Basle Symposium, Editores Roche, pp25-38.

2. Adapted from Rinne, U.K. et al: Levodopa with benserazide or carbidopa in Parkinson Disease. *Neurology* Dec. 1979; 29 (12): 1584-1589.



Hoffmann-La Roche Limited
Etobicoke, Ontario M9C 5J4



CIBA-GEIGY

Award for Excellence in Neurological Science

CIBA-GEIGY is offering an Award for Excellence for the best article published in the Journal within the period of one year.

A cash prize of \$2500 will be announced at the annual meeting of the Canadian Congress of Neurological Sciences in June. Articles published in Volume 19 will be adjudicated by the editorial board for the 1992 award.

ADVERTISERS INDEX

Abbot
Epival - xvi, xix

Allergan
Botox - vii

Ciba/Geigy
Tegretol - obc, xiii, xxi

Deprenyl
Eldepryl - viii, ix
Prolopa - xi, xxiv

Hoescht
Frisium - ibc, iii, xxv

Janssen
Sibelium - iv, v, xviii

Nicolet Instruments - x

Sandoz Canada
Organ Donation - xii
Parlodel - ifc, xx

Syntex
Ticlid - xiv, xv, xvii

Classified Ads
- viii, xxii, xxiii, xxiv

CIBA-GEIGY

ILAE IBE EPILEPTOLOGY PRIZE

CIBA-GEIGY, in cooperation with the International League Against Epilepsy and the International Bureau of Epilepsy, is pleased to announce the CIBA-GEIGY ILAE IBE Epileptology Prize. The prize, worth 20,000 Swiss Francs (about \$20,000), is to be awarded in recognition of outstanding achievement in the field of epilepsy.

Anyone outside the pharmaceutical industry who considers that they made a significant scientific contribution to the field of epilepsy may compete.

Entries will be judged by an Adjudicatory Panel from ILAE and IBE and an independent chairman. Prize will be awarded, July 1993 in Oslo, Norway.

Deadline for submission is January 15, 1993.

Rules and application forms can be obtained by writing to:

CIBA-GEIGY CANADA LTD.

Pharmaceuticals Division

6860 Century Avenue

Mississauga, ON

L5N 2W5

Attention: S. Parks - Epileptology Prize

See page xi

add
IN EPILEPSY
Frisium[®] 10 mg
(clobazam)
TO ACHIEVE SEIZURE CONTROL

Frisium (clobazam) Tablets, 10 mg
THERAPEUTIC CLASSIFICATION Anticonvulsant for adjunctive therapy.
ACTIONS Frisium (clobazam) is a 1,5-benzodiazepine with anti-convulsant properties. In general, the mode of anti-epileptic action of clobazam is probably largely analogous to that of the 1,4-benzodiazepines. The differences between clobazam (a 1,5-benzodiazepine) and the 1,4-benzodiazepines in terms of therapeutic efficacy and neuro-toxicity are possibly due to the variation in degree of the agonist action at the high affinity benzodiazepine receptor or to differing relative action at the high and low affinity benzodiazepine receptors. Regarding the mechanism of action, it is likely that modifications to the function of gamma-aminobutyric acid (GABA) as an important inhibitory neurotransmitter underlie the pharmacological effects of the benzodiazepines. Electro-physiologic studies have shown that benzodiazepines potentiate GABA-ergic transmission at all levels of the neuroaxis, including the spinal cord, hypothalamus, hippocampus, substantia nigra, cerebellar cortex and cerebral cortex. The changes induced by the interaction of GABA with its receptors is enhanced by benzodiazepines, resulting in a decrease in the firing rate of critical neurons in many regions of the brain. The oral absorption of clobazam, like that of all benzodiazepines, is fast and complete. The time to peak concentration ranges from 1 to 4 hours. The administration of food with the drug has variable effects on the rate of absorption. The drug is highly lipophilic and is rapidly distributed in fat and cerebral gray matter. Within 1 to 4 hours of administration it has accumulated in white matter and is then redistributed widely. The volume of distribution is large. Clobazam is extensively metabolized and is not excreted in unchanged form by any species studied. Clobazam forms a number of metabolites with N-desmethyloclobazam being the most important. The half-life of N-desmethyloclobazam is much longer (mean 42 hours; range 36-46 hours) than for clobazam (mean 18 hours; range 10-30 hours). N-desmethyloclobazam reaches higher serum levels, especially with long term administration of clobazam. The half-life increases with the patient's age. The drug is about 85% protein-bound; hepatic disease may alter both the metabolism of the drug and its protein binding thus affecting plasma clobazam levels. There have been no studies that have demonstrated a clear-cut correlation between serum levels of clobazam or of N-desmethyloclobazam to clobazam efficacy. Most reports indicate there is no, or only a very weak, correlation between the clobazam dose, or blood levels, and its clinical effects. Therapeutic blood levels for clobazam are in the range of 50ng - 300ng/mL with the corresponding range for N-desmethyloclobazam being from 1000 - 4000ng/mL. The serum levels at which anti-convulsant effects can be expected are not yet known but it can be assumed that the therapeutic range lies in the order of the figures given above. Since N-desmethyloclobazam blood levels are 10-20 times higher than those for clobazam, and this metabolite also has anti-epileptic effects, it may be more important to the anti-epileptic efficacy of clobazam than the parent compound itself. After oral administration of ¹⁴C-labelled clobazam to man, approximately 90% of the radioactivity was recovered in urine. Seven double-blind studies have been reported in which clobazam was given as adjunctive therapy versus placebo within an established anti-epileptic regimen; clobazam was shown to be significantly superior to placebo.
INDICATIONS Frisium (clobazam) has been found to be of value as adjunctive therapy in patients with epilepsy who are not adequately stabilized with their current anti-convulsant therapy. **CONTRA-INDICATIONS** Hypersensitivity to clobazam, severe muscle weakness (myasthenia gravis) and narrow angle glaucoma. **WARNINGS** Use in the elderly: Frisium (clobazam) should be used with caution in elderly and debilitated patients, and those with organic brain disorders, with treatment initiated at the lowest possible dose. [See Precautions]. **Potentiation of drug effects:** Patients should be cautioned about the possibility of additive effects when Frisium is combined with alcohol or other drugs with central nervous system depressant effects. Patients should be advised against consumption of alcohol during treatment with Frisium. [See Precautions]. **Physical and psychological dependence:** Physical and psychological dependence are known to occur in persons taking benzodiazepines. Caution must be exercised if it is at all necessary to administer Frisium to individuals with a history of drug misuse or those who may increase the dose on their own initiative. Such patients must be placed under careful surveillance. Signs and symptoms of withdrawal may follow discontinuation of use of Frisium; thus it should not be abruptly discontinued after prolonged use. [See Precautions]. **Use in pregnancy:** Frisium should not be used in the first trimester of pregnancy and thereafter only if strictly indicated. Nursing mothers in whom therapy with Frisium is indicated should cease breast-

feeding, since clobazam passes into breast milk. Several studies have suggested an increased risk of congenital malformations associated with the use of minor tranquilizers (chloridiazepoxide, diazepam and meprobamate) during the first trimester of pregnancy. If Frisium is prescribed to a woman of child-bearing potential she should be warned to consult her physician regarding the discontinuation of the drug if she intends to become, or suspects she might be, pregnant. **Anterograde amnesia:** Anterograde amnesia is known to occur after administration of benzodiazepines. **Use in patients with depression or psychosis:** Frisium is not recommended for use in patients with depressive disorders or psychosis. **PRECAUTIONS Driving and Hazardous Activities:** Frisium (clobazam) possesses a mild central nervous system depressant effect, therefore patients should be cautioned against driving, operating dangerous machinery or engaging in other hazardous activities, particularly in the dose adjustment period, or until it has been established that they do not become drowsy or dizzy. **Use in the Elderly:** Elderly and debilitated patients, or those with organic brain syndrome, have been found to be prone to the CNS depressant activity of benzodiazepines even after low doses. Manifestations of this CNS depressant activity include ataxia, oversedation and hypotension. Therefore, medication should be administered with caution to these patients, particularly if a drop in blood pressure might lead to cardiac complications. Initial doses should be low and increments should be made gradually, depending on the response of the patient, in order to avoid oversedation, neurological impairment and other possible adverse reactions. **Dependence Liability:** Frisium should not be administered to individuals prone to drug abuse. Caution should be observed in all patients who are considered to have potential for psychological dependence. Withdrawal symptoms have been observed after abrupt discontinuation of benzodiazepines. These include irritability, nervousness, insomnia, agitation, tremors, convulsions, diarrhea, abdominal cramps, vomiting and mental impairment. As with other benzodiazepines, Frisium should be withdrawn gradually. **Tolerance:** Loss of part or all of the anti-convulsant effectiveness of clobazam has been described in patients who have been receiving the drug for some time. There is no absolute or universal definition for the phenomenon and reports vary widely on its development. The reported success of clobazam in intermittent therapy in catamenial epilepsy implies that tolerance may be minimized by intermittent treatment but long-term follow-up is unreported. No studies have identified or predicted which patients are likely to develop tolerance or precisely when this might occur. **Use in Mental and Emotional Disorders:** It should be recognized that suicidal tendencies may be present in patients with emotional disorders; particularly those depressed. Protective measures and appropriate treatment may be necessary and should be instituted without delay. Since excitement and other paradoxical reactions can result from the use of benzodiazepines in psychotic patients, Clobazam should not be used in patients suspected of having psychotic tendencies. **Use in Patients with Impaired Renal or Hepatic Function:** Clobazam requires dealkylation and hydroxylation before conjugation. Usual precautions should be taken if Frisium is used in patients who may have some impairment of renal or hepatic function. It is suggested that the dose in such cases be carefully titrated. In patients for whom prolonged therapy with Frisium is indicated, blood counts and liver function should be monitored periodically. **Use in Patients with Acute, Severe Respiratory Insufficiency:** In patients with acute, severe respiratory insufficiency, respiratory function should be monitored. **Laboratory Tests:** If Frisium is administered for repeated cycles of therapy, periodic blood counts and liver and thyroid function tests are advisable. **Drug Interactions:** Most studies of the potential interactions of clobazam with other anti-epileptic agents have failed to demonstrate significant interactions with phenytoin, phenobarbital, or carbamazepine. However, one study noted that the addition of clobazam caused a 25% increase in serum drug levels in 29% of patients taking carbamazepine, 63% of patients taking phenytoin, 13% of those taking valproate and 14% of those on phenobarbital. The contradictory findings in different studies are presumably due to variations in patient susceptibility, and although clinically significant interactions are unusual, they may occur. Alcohol may also significantly increase plasma clobazam levels. **Several of the established anti-epileptic agents:** carbamazepine, diphenylhydantoin, phenobarbital, valproic acid, cause the blood levels of clobazam to decrease slightly. Findings are less consistent with regard to N-desmethyloclobazam: serum levels are lower with concurrent valproic acid, but higher with carbamazepine and diphenylhydantoin. **Toxicologic Studies:** In mouse, clobazam was associated with hepatomas in high-dose males. In rat, an increased

incidence of thyroid adenomas was seen in males. There were three malignancies: two (male and female) in the thyroid and one (female) in the liver. (See Carcinogenicity). The relevance of these findings to man has not been established. **ADVERSE REACTIONS** From 19 published studies of Frisium (clobazam) use in epileptic patients, the overall incidence of side-effects was 33% of which drowsiness, dizziness and fatigue were most frequently reported. Canadian experience provides a similar overall incidence (32%) with drowsiness reported in 17.3% of patients, and 12% of patients terminating treatment because of side-effects. The incidence of side-effects was lower in patients under 16 years of age (23.7%) than the incidence in adults (43.1%); p<0.05, whereas treatment discontinuation incidences were similar across age groups: 10.6% and 13.8% respectively. The following side-effects occurred at incidences of greater than 1% (ataxia [3.9%], weight gain [2.2%], dizziness [1.8%], nervousness [1.6%], behaviour disorder [1.4%], hostility and blurred vision [1.3%]) while other effects occurred at a less than 1% incidence. Symptoms of tiredness may sometimes appear, especially at the beginning of treatment with Frisium and when higher doses are used. Also in rare instances and usually only temporarily, the patient may experience dryness of the mouth, constipation, loss of appetite, nausea, dizziness, muscle weakness, disorientation, tiredness, or a fine tremor of the fingers, but also paradoxical reactions, e.g., restlessness and irritability. After prolonged use of benzodiazepines, impairment of consciousness combined with respiratory disorders has been reported in very rare cases, particularly in elderly patients; it sometimes persisted for some length of time. Under experimental conditions, impairment of alertness has been observed to be less pronounced after therapeutic doses of clobazam than after other benzodiazepines. Nevertheless, even when used as directed, the drug may alter reactivity to such an extent as to impair driving performance or the ability to operate machinery, especially when it is taken in conjunction with alcohol. As with other drugs of this type (benzodiazepines), the therapeutic benefit must be balanced against the risk of habituation and dependence during prolonged use. Isolated cases of skin reactions such as rashes or urticaria have been observed. **SYMPTOMS AND TREATMENT OF OVERDOSAGE** Symptoms: The cardinal manifestations are drowsiness, confusion, reduced reflexes, increasing sedation, and coma. Effects on respiration, pulse and blood pressure are noticed with large overdoses. Patients exhibit some jitteriness and overstimulation usually when the effects of the drug begin to wear off. **Treatment:** Immediate gastric lavage may be beneficial if performed soon after ingestion of Frisium (clobazam). Given the route of excretion, [see 'ACTIONS' Section] forced diuresis by short acting 'loop' diuretic may be useful some hours post-ingestion. If respiratory depression and/or coma are observed, the presence of other central nervous system depressants should be suspected. Respiration, pulse and blood pressure should be monitored. General supportive measures aimed at maintaining cardiopulmonary function should be instituted and administration of intravenous fluids started. Hypotension and central nervous system depression are managed by the usual means. **DOSAGE AND ADMINISTRATION** As with other benzodiazepines, the possibility of a decrease in anticonvulsant efficacy in the course of treatment must be borne in mind. In patients with impaired liver and kidney function, Frisium (clobazam) should be used in reduced dosage. **Adults:** Small doses, 5-15 mg/day, should be used initially, gradually increasing to a maximum daily dose of 80 mg as necessary. **Children:** In infants (<2 years), the initial daily dose is 0.5-1 mg/kg/day. The initial dose in children (2-16 years) should be 5 mg/day, which may be increased at 5-day intervals to a maximum of 40 mg/day. As with all benzodiazepines, abrupt withdrawal may precipitate seizures. It is therefore recommended that Frisium be gradually reduced in dose before treatment is discontinued. **Administration:** If the daily dose is divided, the higher portion should be taken at night. Daily doses up to 30 mg may be taken as a single dose at night. **DOSAGE FORM Composition:** Frisium (clobazam) tablets, 10 mg contain clobazam as active ingredient; Lactose, USP; Starch (Corn), NF; Talc, USP; Colloidal Silicon Dioxide, NF; and Magnesium Stearate, NF. **Storage Conditions:** Frisium tablets should be stored in their original containers at room temperature, below 25°C. **Availability:** Frisium is available as white, uncoated, bevelled, round tablets of 7 mm diameter, marked with 'BGL' above and below the scorebreak on the obverse and the Hoechst 'Tower and Bridge' logo on the reverse. Frisium 10 mg tablets are packaged in blisters of PVC film and aluminium foil and are distributed in packs of 30 [3x10] tablets.

Product Monograph available on request.

References:

1. Clobazam in the Treatment of Refractory Epilepsy - The Canadian Experience: The Canadian Clobazam Cooperative Group. In press *Epilepsia*, 1991. Data on file Hoechst Canada Inc.
2. Shorvon, S.D.: Benzodiazepines - clobazam. *Antiepileptic Drugs*, 3rd ed., 1989.

2475/9011/E

PAAB

Ⓜ, Hoechst and Ⓞ, Reg. Trademarks of Hoechst AG, Germany

Hoechst Canada Inc., Montreal H4R 1R6

Hoechst 

See pages iii

(XXV)

FROM
INNOVATIVE
HOECHST
RESEARCH

Frisium[®] 10 mg

(clobazam)

ANTICONVULSANT FOR ADJUNCTIVE THERAPY

EFFICACY

- **Frisium** is efficacious in all seizure types in both pediatric and adult patients.¹
- **Frisium** achieves complete control in up to 30% of refractory patients depending on seizure type.¹

SAFETY

- Adverse events are generally mild and transient.²
- Clinically significant drug interactions are uncommon.
- Impairment of alertness is less pronounced with **Frisium** than with other benzodiazepines.*

DOSAGE

- Daily doses up to 30 mg may be taken as a single dose at bedtime.

IN EPILEPSY

add **Frisium[®] 10 mg**
(clobazam)

TO ACHIEVE SEIZURE CONTROL

PAAB

* Please consult precautions statement in product monograph.

 , Hoechst and ®, Reg. Trademarks of Hoechst AG, Germany

Hoechst Canada Inc., Montreal H4R 1R6

Hoechst 



There are ways of telling when a young epilepsy patient is on Tegretol® CR.

Excellent Seizure Control.

Tegretol CR (controlled-release carbamazepine) controls seizures in many patients—with little impact on cognitive function.^{1,2,3,4} Unlike drugs such as phenytoin, Tegretol CR can leave many patients free to think clearly and do their best.^{1,2,3,4}

Consistent Blood Levels.

Tegretol CR delivers fewer “peaks and valleys” in blood levels than conventional Tegretol. That means fewer side effects and a more stable pattern of cognitive functioning.^{5,6}

Convenient B.I.D. Dosing.

When initiating or switching therapy, consider Tegretol CR. It comes in easy-to-break 200mg and 400mg tablets for dosage flexibility, and offers B.I.D. dosing to enhance patient compliance.



TEGRETOL® CR.
Helping epilepsy patients reach their full potential.

Geigy Mississauga, Ontario L5N 2W5

PAAB MEMBER
 CCFP PMAC G-92111E